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ABSTRACT OF DISSERTATION 
 
 
 
 
NONLINEAR HIERARCHICAL MODELS FOR LONGITUDINAL EXPERIMENTAL 
INFECTION STUDIES 
Experimental infection (EI) studies, involving the intentional inoculation of 
animal or human subjects with an infectious agent under controlled conditions, have a 
long history in infectious disease research. Longitudinal infection response data often 
arise in EI studies designed to demonstrate vaccine efficacy, explore disease etiology, 
pathogenesis and transmission, or understand the host immune response to infection. 
Viral loads, antibody titers, symptom scores and body temperature are a few of the 
outcome variables commonly studied. Longitudinal EI data are inherently nonlinear, 
often with single-peaked response trajectories with a common pre- and post-infection 
baseline. Such data are frequently analyzed with statistical methods that are inefficient 
and arguably inappropriate, such as repeated measures analysis of variance (RM-
ANOVA). Newer statistical approaches may offer substantial gains in accuracy and 
precision of parameter estimation and power. We propose an alternative approach to 
modeling single-peaked, longitudinal EI data that incorporates recent developments in 
nonlinear hierarchical models and Bayesian statistics. We begin by introducing a 
nonlinear mixed model (NLMM) for a symmetric infection response variable. We 
employ a standard NLMM assuming normally distributed errors and a Gaussian mean 
response function. The parameters of the model correspond directly to biologically 
meaningful properties of the infection response, including baseline, peak intensity, time 
to peak and spread. Through Monte Carlo simulation studies we demonstrate that the 
model outperforms RM-ANOVA on most measures of parameter estimation and power. 
Next we generalize the symmetric NLMM to allow modeling of variables with 
asymmetric time course. We implement the asymmetric model as a Bayesian nonlinear 
hierarchical model (NLHM) and discuss advantages of the Bayesian approach. Two 
illustrative applications are provided. Finally we consider modeling of viral load. For 
several reasons, a normal-errors model is not appropriate for viral load. We propose and 
illustrate a Bayesian NLHM with the individual responses at each time point modeled as 
a Poisson random variable with the means across time points related through a Tricube 
mean response function. We conclude with discussion of limitations and open questions, 
and a brief survey of broader applications of these models. 
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CHAPTER ONE 
Literature Review 
 
 
1.1.  INTRODUCTION 
 In a 1951 article in Scientific American, the eminent Australian virologist Sir 
Frank MacFarlane Burnet sounded the death knell for infectious disease, writing:  
One can think of the middle of the twentieth century as the end of one of the most 
important social revolutions in history, the virtual elimination of infectious 
diseases as a significant factor in social life (Burnet 1951). 
At the time there was just cause for such optimism. The preceding hundred years had 
brought astounding advances in the understanding of the etiology of infectious diseases 
and their prevention. Robert Koch and Louis Pasteur, in the latter half of the 19
th
 century, 
had established that diseases such as anthrax, rabies, tuberculosis and cholera were 
caused by microorganisms and had successfully developed vaccines and medications to 
prevent infection (Koch 1884, Koch 1890a, Koch 1890b, Pasteur 1881, Suzor 1887). 
Smallpox vaccination programs had eliminated nearly all cases of that disease in the 
United States (Chapin 1913). Alexander Fleming had discovered penicillin in 1929 and 
subsequent work by Howard Florey, Ernst Chain and Norman Heatley made possible its 
mass production. At the same time Burnet wrote the above words, Jonas Salk was on the 
verge of commencing human testing of his killed-virus polio vaccine (Meldrum 1998).  
However over the next forty years this confidence in the elimination of infectious 
disease would be steadily eroded. While many diseases were being successfully 
controlled, novel viruses were emerging. Examples include Ebola virus in the 1970’s 
(Simpson et al. 1978), the human immunodeficiency virus (HIV) in the early 1980’s 
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(Barre-Sinoussi et al. 1983), and more recently the severe acute respiratory syndrome or 
SARS (Fouchier et al. 2003) and the Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV). Furthermore, it quickly became apparent that bacteria were far more 
resourceful than previously realized. As early as 1942 came the first reports of penicillin-
resistant strains of Staphylococcus aureus (Rammelkamp and Maxon 1942). Within two 
decades as many as 80% of staphyolococcal isolates were resistant to penicillin (Lowy 
2003). In light of developments such as these, it has become clear that infectious disease 
research, epidemiology and prevention are as relevant and important as ever.  
Experimental infection (EI) studies, involving the intentional inoculation of 
animal or human subjects with an infectious agent under controlled conditions, have 
played a central role in infectious disease research and epidemiology for more than two 
hundred years. Most of the early work of Koch and Pasteur cited above involved the 
experimental inoculation of small mammals such as rabbits and guinea pigs. Today there 
are hundreds of animal challenge models for infectious diseases (Zak and O’Reilly 1993). 
But experimental infection studies are not limited to animals. Certain diseases lack 
effective animal models, and even when they do exist, human models are often preferred 
when they can be safely and ethically employed. Human challenge models are used to 
study self-limiting respiratory infections such as rhinovirus, influenza and respiratory 
synctitial virus (Ramos et al. 2014, DeVincenzo et al. 2014, Wilkinson 2012), and 
models have been developed or proposed for Helicobacter pylori (Michetti 2004), cholera 
(Shirley and McArthur 2011), malaria (Sauerwein et al. 2011), gonorrhea (Hobbs et al. 
2011), tuberculosis (Hokey 2014) and others. 
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In early EI studies the outcome of interest was usually the simple presence or 
absence of disease. Eventually investigators became interested in studying the time 
course of various aspects of the infection response. A major milestone in the development 
of a polio vaccine, for instance, was Dorothy Horstmann’s 1952 time course EI study 
which demonstrated the occurrence of viremia in monkeys following oral inoculation 
with poliomyelitis virus (Horstmann 1952). The knowledge that the virus reached the 
nervous system via the bloodstream led researchers to focus on development of an oral 
polio vaccine that would to elicit antibodies in the blood and gastrointestinal tract 
(Carleton 2011). 
With advances in microbiology and technology, increasingly sophisticated 
questions are being investigated using time course EI studies. Yet the statistical 
approaches used to model and analyze time course data from EI studies have remained 
largely unchanged for at least thirty years, despite major advances in methods for 
analyzing longitudinal data that have occurred during that period. The most popular 
approaches traditionally have been 1) the analysis of variance for repeated measures 
(RM-ANOVA) and 2) multiple horizontal or vertical contrasts (Ludbrook 1994) using t-
tests or their nonparametric equivalents (Paillot et al. 2013, Munhoz et al. 2012, Cray et 
al. 1995, Suter et al. 1985, Higgins et al. 1983). The aim of this dissertation is to propose 
an alternative approach to the analysis of longitudinal data from EI studies that draws 
upon recent developments in the areas of nonlinear hierarchical models and Bayesian 
statistics.  
We begin by reviewing the various roles that EI studies have played in the study 
of infectious diseases. Next we narrow our focus by describing in detail four time course 
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EI studies on which we will draw in subsequent chapters for illustrative examples of our 
methods. We review some objections that have been raised to traditional methods of 
analyzing data from such experiments. Finally we outline the specific aims of this 
dissertation.  
1.2.  A BRIEF OVERVIEW OF THE USES OF EXPERIMENTAL INFECTION 
STUDIES 
Long before the causal link between microorganisms and disease had been 
decisively proven, physicians and scientists were conducting EI studies. In 1796, in one 
of the earliest tests of vaccine efficacy, England physician Edward Jenner challenged an 
eight year-old boy with live smallpox two months after inoculating him with cowpox 
vaccine (Riedel 2005; Willis 1997).  As part of his work on a rabies vaccine in the latter 
part of the nineteenth century in France, Pasteur performed EI studies on rabbits (Franco 
2013). In the mid-twentieth century polio research and vaccine development relied 
heavily on the experimental infection of monkeys (Oshinsky 2006). Several candidate 
cholera vaccines have been tested in human challenge trials (Shirley and McArthur 2011, 
Herrington et al. 1990 Tacket et al. 1990). Recently, controlled human malaria infection 
has been used as a method of evaluating candidate malaria vaccines (Laurens et al. 2012, 
Roestenberg et al. 2013, Targett et al. 2013).  Human challenge models for self-limiting 
respiratory infections such as influenza, human rhinovirus and respiratory synctitial virus 
are being used to accelerate proof of concept for vaccines against respiratory viruses 
(Ramos et al. 2014, DeVincenzo et al. 2014). 
Many early EI studies were concerned with establishing the infectious etiology of 
a known disease. In a historic lecture in 1882, Koch demonstrated the infectious etiology 
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of tuberculosis and identified the causative agent, Mycobacterium tuberculosis. His 
discovery was accomplished by experimentally infecting guinea pigs with material from 
tuberculosis-infected human and animal sources (Koch et al. 1982). Similarly, his work 
on the etiology of anthrax involved the experimental infection of mice with Bacillus 
anthracis (Koch 1876). Koch would subsequently publish his postulates for causation in 
1890. Since that time, EI studies have been used to demonstrate the etiological agents for 
many infectious disease. More recently an etiologic link between Helicobacter pylori, a 
gastrointestinal bacterium which was discovered in 1982 (Marshall and Warren 1984), 
and type B gastritis has been established largely through EI studies in both human 
volunteers and animal models (Blaser 1990).  
Another historically important use of experimental infection has been to establish 
the route by which an infectious agent is transmitted to the host. Carlos Finlay in 1881 
proposed that the Culex mosquito was the agent responsible for the transmission of 
yellow fever mosquito (Finlay 1881). To test his hypothesis he conducted a series of 102 
experimental infections of human volunteers, the results of which were generally viewed 
as inconclusive (Sternberg1891, Sternberg 1901). His experiments were subsequently 
repeated, and his theory confirmed, in further human volunteer experiments led by Walter 
Reed (Reed et al. 1900). Contemporary with Finlay and Reed, Ronald Ross 1897 
conducted EI studies in birds to demonstrate transmission of malaria parasites by 
mosquito (Bynum 1999). Killingley et al (2011) recently reviewed the potential 
contributions of human challenge studies to research on mechanisms of influenza 
transmission. 
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EI studies have played a central role in experimental immunology, where they 
have helped to advance basic understanding of the immune response to infection. 
Representative examples include Wilkinson et al. 2012; Henriques et al. 2012; Gaunt et 
al. 2010; McMichael et al. 1981. Numerous journals, including Viral Immunology, 
Vaccine, Journal of Immunology and others, are dedicated to clinical, translational and 
basic research into the immune response to viral infections.   
  
Figure 1.1.  Google Scholar references containing the phrase 
“experimental infection” in the title by decade, 1890-2009 
Scholarly papers containing the phrase “experimental infection” can be found 
from as early as 1899. Figure 1.1 shows the number of references by decade retrieved by 
Google Scholar (2013) containing the phrase “experimental infection” in the title. The 
number of published studies rose gradually through the mid-1940’s and then increased 
dramatically over the next four decades.  This data indicates that hundreds of EI studies 
are currently being published annually in peer-reviewed journals around the world. The 
applications discussed in this section – vaccine efficacy, etiology, transmission and basic 
immunology – represent only some of the most common applications. 
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1.3.  EXPERIMENTAL INFECTION CASE STUDIES 
 The focus of this dissertation is EI studies in which the response variable is 
measured repeatedly on one or more groups of subjects over time. We will refer to such 
experiments as repeated measures, time course, or longitudinal EI studies. In this section 
we give detailed descriptions of four recent longitudinal EI studies. These case studies 
will provide context for the discussion of our research aims as well as background for the 
illustrative examples in subsequent chapters. We consider these examples to be a 
representative cross-section of mainstream approaches to analyzing time course data from 
EI studies. Later chapters will explore alternative methods. 
1.3.1.  The role of host genetic factors in the pathogenesis of Equine Viral Arteritis 
Equine arteritis virus (EAV) is the causative agent of a respiratory and 
reproductive disease of equids known as equine viral arteritis (EVA). The virus was first 
isolated in 1953 on a Standardbred breeding farm in Bucyrus, Ohio during an outbreak of 
respiratory illness and abortion (Doll et al. 1957). Numerous other outbreaks have 
occurred throughout the world since that time, including an epizootic among 
thoroughbreds in Kentucky in 1984 (Timoney et al. 1986). EAV is a major concern to 
horse breeders because it can cause spontaneous abortion in mares and temporary 
subfertility in stallions. Furthermore, 30% to 70% of exposed stallions will become long-
term carriers of the virus, continuing to shed virus in semen after all clinical signs of 
infection have ceased (Timoney et al. 1986). Such carrier stallions constitute the natural 
reservoir for EAV, and venereal transmission from a carrier stallion, either directly or via 
artificial insemination, is the source of many outbreaks. The virus is also transmitted via 
the respiratory route (Holyoak et al. 2008). 
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It has been observed in natural outbreaks that the severity and clinical signs of 
EVA show considerable variation, both among individual horses in the same outbreak 
and between different outbreaks. Numerous factors may influence the course of infection 
including the age and physical condition of the horse, the viral strain and the received 
dose (Balasuriya et al. 2007, Holyoak et al. 2008). Recently it has been proposed that 
host genetic factors may also play a role in EAV pathogenesis. Balasuriya and colleagues 
have identified a haplotype that is associated with susceptibility of CD3+ T lymphocytes 
to infection by a recombinant virulent Bucyrus strain (VBS) of EAV. They classified 
horses as possessing the “resistant” or “susceptible” phenotype based on the ability of the 
VBS to infect in vitro their CD3+ T lymphocytes (Go et al. 2010). Recently, they 
conducted two related experiments to assess whether the response to EAV infection 
differs between horses with the resistant and susceptible phenotypes.  
1.3.1.1.  “Assessment of correlation between in vitro CD3+ T cell susceptibility to 
EAV infection and clinical outcome following experimental infection”  
In the first experiment, by Go et al. (2011), four mares possessing the in vitro 
susceptible CD3+ T cell phenotype were identified along with four possessing the 
resistant phenotype. All eight mares were inoculated with the recombinant, virulent 
Bucyrus strain of EAV. Clinical signs, viral load, complete blood cell counts and serum 
neutralizing antibodies were monitored over a period of seven weeks, which included a 
seven-day baseline observation period. We focus here on comparison of the mean febrile 
response in the two groups as measured by core body temperature (CBT), which was 
observed on the morning of days -7, -4 and -2 prior to inoculation and on both morning 
and evening of days 0, 2, 4, 6, 8, 10, 12 and 14 post-inoculation (DPI). Figure 1.2 
presents the observed febrile responses for all four mares in each group.  
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Figure 1.2. Observed core body temperature profiles by phenotype group for eight mares 
following experimental challenge with EAV (Go et al. 2011) 
 
 
Figure 1.3. Mean core body temperature by phenotype group. Significant differences 
(𝑝 < 0.05) were reported on days 7 and 9 based on RM-ANOVA with post-hoc testing 
for group differences by Holm-Sidak method
1
.  
                                               
1 Reprinted from Veterinary Microbiology 2012;157(1-2), Go et al, Assessment of correlation between in 
vitro CD3+ T cell susceptibility to EAV infection and clinical outcome following experimental infection, 
pages 220-225, Copyright 2012, with permission from Elsevier. 
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A global test of the hypothesis of no group difference in febrile response was 
conducted using two-way repeated measures analysis of variance (RM-ANOVA).  The 
Holm-Sidak method (Holm 1979) was subsequently used to identify specific time points 
at which CBT differed significantly between phenotype groups. Significant differences 
(𝑝 < 0.05) were reported on days 7 and 9 (Figure 1.3). These findings were taken as 
evidence of an association between CD3+ T lymphocyte phenotype and febrile response.  
1.3.1.2. “Semen quality of stallions challenged with the Kentucky 84 strain of equine 
arteritis virus” 
The findings of a follow-up to the Go experiment with similar design, but using 
stallions instead of mares and a different strain of EAV, were published by Campos et al. 
in 2014.  One of the primary aims of that experiment (the results of which have not been 
published to date) was to assess whether the CD3+ T cell phenotype may play a role in 
development of the long-term EAV carrier state in the stallion. Although not the primary 
focus of that particular paper, febrile response and other clinical signs were also recorded 
as was done in Go et al. (2011). 
In Chapters 2 and 3 we re-analyze the EAV febrile response data from the two 
experiments by Go and Campos. 
1.3.2. Effects of rhinovirus infection in chronic obstructive pulmonary disease 
 The first human rhinoviruses (HRV) were discovered in the 1950’s. Since that 
time 99 serotypes have been identified. HRV is the most common cause of upper 
respiratory infection worldwide. In recent years, rhinovirus infection has also been 
implicated as an important factor in exacerbations of asthma and chronic obstructive 
pulmonary disease (COPD) (Henderson 2013).  
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To overcome the difficulties involved in studying the role of respiratory infections 
in naturally occurring exacerbations, researchers have developed human challenge 
models. Studies employing HRV challenge models in asthma include those by Message 
et al. (2008); Contoli et al. (2006); Wark et al. (2005), Grunberg et al. (2001) and Bardin 
et al. (2000).  
Similarly, Mallia and colleagues (2006, 2011, 2012, 2013) have developed an 
HRV challenge model for COPD. For their 2011 study, thirteen volunteers with COPD 
and thirteen controls with a similar smoking history, but normal lung function, were 
recruited. All participants tested negative for serum neutralizing antibodies to rhinovirus 
16 (RV-16). All twenty-six subjects were inoculated with a 10 TCID50 dose of RV-16 
and followed for six weeks post-infection. Viral loads in nasal lavage and sputum, lung 
function, inflammatory markers, and upper and lower respiratory symptom scores were  
sampled at varying intervals and intensities. Twenty-three subjects displayed virological 
evidence of rhinovirus infection: eleven from the COPD group and twelve from the 
control group. Data from those 23 subjects were analyzed to assess whether experimental 
RV-16 infection induces exacerbation in persons with COPD.  
Figure 1.4 presents the observed, individual profiles of viral load in nasal lavage 
(VLN) following inoculation over the course of six weeks. For most subjects, VLN 
increased to a peak very rapidly returned to baseline (zero) more gradually, as the host 
immune response neutralized and eliminated the virus.  The figure suggests that the mean 
time to complete viral clearance may be greater in the control group – although this 
impression is based largely on just two control subjects with clearance times greater than 
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thirty days – and that the peak viral load may be slightly higher in the COPD group. 
Figure 1.5 displays the group means at each measurement occasion. 
Figure 1.4. Observed profiles of viral load in nasal lavage for eleven subjects with COPD 
and twelve health controls following experimental challenge with RV-16 
 
 
Figure 1.5.  Mean viral load in nasal lavage for COPD and control groups 
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In the original experiment, tests for differences in the population mean response at 
each time point were analyzed using unpaired t tests or nonparametric Mann-Whitney 
tests. No adjustment for multiple comparisons was mentioned. Despite higher observed 
mean VLN in the COPD group on days 3 through 12, the authors reported a significant 
difference (P < 0.05) in population mean viral load on day 6 only. Thus there is some 
uncertainty about the interpretation of these findings. Group differences in age, gender 
and smoking status further complicate interpretation. We revisit the HRV viral load data 
in Chapter 4. 
1.3.3. Effect of body condition on viral shedding in migratory birds 
Mallard ducks (Anas platyrhynchos) are an important reservoir for influenza A 
virus (IAV), and their migration is a key factor in its global transmission (Webster et al. 
1992). The physical strain of migration can cause declines in the birds’ body condition 
which may impair immune function
 
(Latorre-Margalef et al. 2009a, Flint and Franson 
2009, Latorre-Margalef et al. 2009b). Arsnoe and colleagues conducted an MC 
experiment to test the hypotheses that reduced body condition is associated with 
increased susceptibility to infection with IAV and with increased peak viral load and 
duration of infection
 
(Arsnoe et al. 2011). Thirty seronegative wild-caught mallards were 
randomly assigned to three treatment groups. By controlling food availability over a 
period of several weeks, differing levels of body condition were established in each 
group. Birds in the “normal” treatment group were maintained at ±5% of their baseline 
body mass; birds in the “lean” treatment group at −10% of baseline body mass; and birds 
in the “poor” treatment group at −20% of baseline body mass. A fourth treatment group 
consisted of ten captive-bred mallards given the normal treatment described above. Thus 
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four treatment groups were established: wild normal, wild lean, wild poor and captive-
bred. 
When target condition levels were reached, all birds were inoculated with 1.5 mL 
of 10
6
 PFU/mL low pathogenic AIV [strain A/Northern pintail/California/44221-
761/2006 (H5N9)]. Body conditions were maintained over the course of the experiment. 
Viral shedding in pooled cloacal and oral swabs was measured by PCR and expressed in 
units of 𝑙𝑜𝑔10(genome equivalent copy numbers), or 𝑙𝑜𝑔10(𝐺𝐸𝐶), per 140 𝜇𝑙  of swab 
fluid. Samples were collected on the first three days post-inoculation and every two days 
thereafter until 28 DPI. Mean shed virus by treatment group is presented in Figure 1.7. In 
general, groups with higher condition levels (i.e. greater food availability) shed more 
virus.  
In original analysis, RM-ANOVA was used to compare virus excretion over the 
first five DPI. Significant variation among groups was detected (𝐹2,25, 𝑝 = 0.013). Post-
hoc group comparisons were carried out using Tukey’s Honestly Signficant Difference 
procedure. The only reported difference was that birds in the wild poor treatment group 
shed less virus than birds in the wild normal treatment group (M=2.3, p=0.010). 
Figure 1.7 presents the individual viral shedding profiles for the captive-bred 
control group and the wild lean treatment group. There is considerable inter-individual  
variability in shedding patterns, with one of the wild lean birds shedding high levels of 
virus and several of the control birds showing low levels. In Chapter 4 we analyze the 
viral shedding data in Figure 1.7. 
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Figure 1.6. Mean shed virus by treatment group 
 
Figure 1.7. Observed viral shedding profiles for nine captive bred ducks with normal 
body condition and nine wild-caught ducks with lean body condition following 
experimental challenge with AIV (observations for days 11 through 28 not shown) 
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1.4.  LONGITUDINAL EI DATA 
1.4.1.  Nature of longitudinal EI data 
Unlike many types of longitudinal data, experimental infection data are inherently 
nonlinear, as exemplified by Figures 1.2 through 1.7. We restrict attention in this 
dissertation to experiments in which there is exactly one challenge point. In such 
experiments, for quantities such as body temperature or viral load there is typically a 
brief post-challenge incubation period followed by an interval of rapid increase (the 
“onset” phase of the response). As the host’s immune system responds to the infection, 
the increase slows and eventually peaks. This is followed by a return to the pre-challenge 
baseline level (the “recovery” phase). In the case of viral load typically the level returns 
to zero, whereas body temperature will return to the host’s normal baseline level, which 
will vary slightly from one individual to the next. This pattern has been referred to as a 
single-peaked response to distinguish it from growth curve data
 
(Matthews et al. 1990). 
Peaked responses may take other forms, but the present paper focuses on single-peaked 
responses with a common pre- and post-challenge baseline level. 
Another way in which data arising from EI experiments differs from traditional 
longitudinal data is in the frequency with which responses are sampled. Clinical signs 
such as core body temperature or symptom scores are routinely observed on twenty or 
more occasions over a period of several weeks or months. Furthermore, advances in 
biomedical technology have made practical the intensive sampling of viral loads and 
various markers of the host immune response
 
(Schochetmann et al. 1988). 
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1.4.2. Traditional approach to the analysis of longitudinal EI data 
Prior to 1980, repeated measurements data from experimental infection studies 
were commonly presented without statistical analysis. By the late 1970’s investigators 
were beginning to employ basic statistical methods for comparing group mean responses 
(Makinde and Wilkie 1979; Higgins et al. 1983).  By the mid-to-late 1990’s formal 
statistical analyses had become the norm for EI studies, RM-ANOVA apparently being 
the default method (Paillot et al. 2013; Munhoz et al. 2012; Cray and Moon 1995). 
However it is unclear whether, among practitioners, much critical thinking has gone into 
that decision or whether RM-ANOVA is simply used because it is familiar and 
straightforward to use. 
Among statisticians the application of RM-ANOVA data to longitudinal data, in 
general, has been criticized on several grounds
 
(Matthews et al. 1990, Gueorguieva and 
Krystal 2004, Fitzmaurice and Ravichandran 2008). There are concerns about the validity 
of certain underlying statistical assumptions. Furthermore, in the case of peaked data, it is 
readily apparent that any approach that involves averaging a group of single-peaked 
response profiles at each time point will tend to distort the very features of the infection 
response that are of greatest interest. Such naïve averaging will tend to produce estimated 
population response curves that understate peak intensity and overstate response duration, 
as has been described recently by DeVincenzo and colleagues (2010). This effect will 
increase as the variability in the time to peak response among subjects increases. 
1.4.3.  Alternative approaches to data analysis    
  Numerous alternatives to RM-ANOVA for analyzing longitudinal data exist, most 
notably including summary measures or response feature analysis (Matthews et al. 1990), 
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multivariate analysis of variance (MANOVA) and the linear mixed model. Each has 
strengths and weaknesses which depend on the particulars of the experimental design. 
Summary measures may be viable when the individual response profiles can be reduced 
to a single, meaningful measure, such as summarizing a linear trajectory by its slope. But 
a peaked response curve has numerous features of potential interest which cannot all be 
encompassed in a single measure.  
MANOVA has the advantage that, unlike RM-ANOVA, it does not impose a 
restrictive assumption about the covariance structure of individual response vectors. 
Instead, an individual’s responses are treated as a vector arising from a multivariate 
normal distribution, the covariance structure of which can be explicitly specified by the 
analyst. However MANOVA requires larger numbers of individuals per group to equal 
the power of RM-ANOVA, and becomes increasingly unattractive as the number of 
observations per individual increases.  
The linear mixed model (LMM) retains the ability to specify an appropriate 
individual covariance structure. Moreover, if the individual response trajectories are 
linear, the performance of the LMM improves as the number of measurement occasions 
increases, rather than degrading as with MANOVA. However with a nonlinear response, 
time in the LMM must be treated as a factor, which negates this advantage.   
 Nonparametric regression is an option that is capable of modeling the mean 
response curve quite flexibly (Wu and Zhang 2006). Campos et al. (2014) provides an 
example of this approach applied to data from an EI study. However the parameters in 
nonparametric models (and RM-ANOVA models also) bear no relationship to quantities 
of biological interest – such as the timing and intensity of the peak response, and the 
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response onset, recovery and duration – which limits inferential options. We propose 
another alternative, the nonlinear hierarchical model (NLHM), which among other 
features (a) permits direct modeling of the nonlinear mean response trajectories, (b) 
allows for meaningful parameterization of the response function, and (c) allows for 
flexible modeling of the covariance structure for individual response vectors.   
1.5. NONLINEAR HIERARCHICAL MODELS FOR LONGITUDINAL EI DATA 
1.5.1.  Background  
Nonlinear hierarchical models (NLHM) have a history of application in 
population pharmacokinetics and pharmacodynamics research (PopPK-PD) dating back 
to the early 1970’s (Sheiner et al .1972). Pharmacokinetics is the study of drug 
absorption, distribution, metabolism and excretion (Roe 1997).  A primary aim of PopPK 
modeling is to understand how patient characteristics affect these processes. 
Concentration is measured repeatedly over time in a sample of patients following 
ingestion of the drug. A NLHM is used to estimate the response of a typical patient as 
well as the degree of variation among individual responses and the influence of factors 
such as patient age, gender, and body weight on response parameters. Pharmacodynamics 
is concerned with the effects of a drug on the patient. The purpose of a PopPD model is 
to relate dose or drug concentration to pharmacodynamics effects of the drug (Bonate 
2011). In 1980 Sheiner and Beal released NONMEM, a software package for NONlinear 
Mixed Effects Modeling which has become the standard for PopPK-PD modeling. An 
extensive literature on NLHM’s for PopPK-PD has developed over the past four decades. 
Several developments since the early 1990’s have made the NLHM accessible to 
a wider audience and increased its range of application. Textbooks on the NLHM were 
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published by Davidian and Giltinan in 1995 and Vonesh and Chinchili in 1997. SAS 
Version 7, released in 1998, introduced the NLMIXED procedure. In 1999 Pinheiro and 
Bates released their package ‘nlme’ (Linear and Nonlinear Mixed Effects Models) in S-
Plus and subsequently released a version for R, and in 2000 they published an 
accompanying textbook. Bayesian implementation of the NLHM has also been facilitated 
in recent years by the introduction of software packages for fitting Bayesian models using 
Markov Chain Monte Carlo sampling methods, such as BUGS (Bayesian Inference Using 
Gibbs Sampling) (MRC Biostatistics Unit 1989), WinBUGS (Lunn et al. 2000), JAGS 
(Just Another Gibbs Sampler) (Plummer 2003) and Stan (Stan Development Team 2014). 
As a result of these developments, since Sheiner and colleagues’ seminal work on 
PopPK-PD the NLHM has been applied to a number of other areas in which nonlinear 
repeated measurements arise. Davidian and Giltinan (2003) provided a review of several 
of these including dairy science, forestry, toxicokinetics, prostate cancer, circadian 
rhythms, cardiology, fisheries science and plant and soil sciences. Of particular relevance 
to this dissertation is the application of the NLHM to the dynamics of human 
immunodeficiency virus (HIV) (Perelson et al. 1996, Wu et al. 1998, Fitzgerald et al. 
2002, Huang 2013). The work on HIV dynamics has led to similar efforts to model 
Hepatitis B and C viral dynamics (O’Sullivan et al. 2008, Snoeck et al. 2010). In all three 
instances the focus is on the changes in viral load over time that can occur in chronically 
infected individuals. We are unaware of any previous efforts to apply the NLHM to the 
analysis of data from EI studies involving the intentional challenge of previously 
uninfected individuals. 
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In the following section we give a brief overview of one form of the NLHM 
which Vonesh and Chinchilli (1997) have referred to as the normal-errors NLHM. We 
adopt their descriptive term for this model and discuss it in the context of EI studies. 
1.5.2. The normal-errors NLHM 
Suppose that infection responses for 𝑛  individuals are sampled on multiple 
occasions. Let 𝑚𝑖  represent the number of sampling occasions for individual 𝑖 . Let 𝑗 
index the sampling times 𝑡1, 𝑡2,⋯ , 𝑡𝑚𝑖  for individual 𝑖 . Denote the responses for 
individual 𝑖 as 𝑦𝑖1, 𝑦𝑖2,⋯ , 𝑦𝑖𝑚𝑖, and a vector of covariates for individual 𝑖 at time 𝑗 as 𝒙𝑖𝑗. 
The covariate vectors will include the sampling times, at a minimum, and may also 
include measurements on factors other than time – such age, gender or smoking status – 
thought to influence an individual’s response to infection. The individual mean infection 
response profiles are modeled as a nonlinear function 𝑓 of the covariate vectors 𝒙𝑖𝑗 and a 
parameter vector 𝜷𝑖  which is unique to each individual. The model for the individual 
infection responses can expressed in terms of the distribution of the response for 
individual i at time t.  
Level 1 (model of intra-individual variability) 
𝑦𝑖𝑗~𝑁(𝜇𝑖𝑗 , 𝜎
2),          𝜇𝑖𝑗 = 𝑓𝑖(𝒙𝑖𝑗 , 𝜷𝑖)     (1.1) 
 In the normal-errors NLHM, intra-individual deviations from the mean response 
trajectory are assumed to follow a multivariate normal distribution. In the form specified 
in (1.1), it is further assumed that these errors are independent and identically distributed. 
It is possible to relax this assumption and allow for both correlation and heterogeneity in 
the intra-individual errors. The interested reader is referred to Davidian and Giltinan 
(1995) for details. 
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At Level 2 of an NLHM we specify a mechanism by which the individual 
response profiles are assumed to be related. This is accomplished by imposing a model 
on the response parameters 𝜷𝑖.  A common practice is to assume that they arise from a 
multivariate normal distribution with mean 𝜷 and variance-covariance matrix 𝑫 . (We 
will refer to the components of 𝜷 as the population infection response parameters and the 
components of 𝜷𝑖 as the individual infection response parameters.)  If all individuals in 
the study belong to a single group, then the model of inter-individual variability can be 
expressed as follows. 
Level 2 (model of inter-individual variability – one group) 
𝜷𝑖 = 𝜷 + 𝒃𝑖 ,         𝒃𝑖~𝑁(𝟎, 𝑫)        (1.2) 
Often in an MC experiment the primary objective is to compare the population 
response profiles for two groups – say treatment vs. placebo or presence vs. absence of a 
genetic trait thought to influence the response to infection – and interest in the individual 
response profiles is secondary. Suppose that the 𝑛 individuals are assigned to two groups 
indexed by 𝑔 ∈ {1,2}, and that individual i belongs to group 𝑔.  For each group define a 
population parameter vector 𝜷(𝑔) which is assumed to give rise to the individual response 
vectors for members of group 𝑔. The Level 2 model can then be written as follows. 
Level 2 (model of inter-individual variability – two groups) 
𝜷𝑖 = 𝜷
(𝑔) + 𝒃𝑖,      𝒃𝑖~𝑁(0,𝑫
(𝑔))      (1.3) 
If we assume that the variance structure is same in both groups then we have 
𝜷𝑖 = 𝜷
(𝑔) + 𝒃𝑖,          𝒃𝑖~𝑁(0,𝑫)      (1.4) 
Thus, the normal-errors NLMM provides estimates of the population response 
function (or functions) through 𝜷 (or 𝜷(𝑔)), estimates of the individual response functions 
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through the 𝜷𝒊, and estimates of both the intra-individual and inter-individual response 
variability through 𝜎2 and 𝑫 (or 𝑫(𝑔)). In the two-sample infection response model, the 
components of the population response parameters 𝜷(𝑔)  can be contrasted to test for 
differences in the peak response, time to peak response, and response onset, recovery or 
duration between two groups. 
The version of the normal-errors NLMM described above permits a great deal of 
flexibility in the specification of both the form of the individual infection responses and 
the nature of the relationship among them. The model can be extended to make it still 
more general. It is possible, for example, to allow for the dependence of the individual 
infection response parameters in 𝜷𝑖 on subject characteristics such as age or gender. One 
can also specify distributional assumptions on the 𝜷𝑖 other than multivariate normality, or 
indeed to avoid distributional assumptions at Level 2 altogether by specifying a 
nonparametric or semiparametric model for 𝜷𝑖. The interested reader is again referred to 
Davidian and Giltinan (1995) for details.  
1.5.3.  Application to EI studies 
Kernel functions provide a convenient class of models for a single-peaked 
infection response. Figure 1.8 presents three common kernel functions: the Gaussian, 
Tricube and Epanechnikov. Each is bounded and symmetric, with a single peak. The 
Gaussian kernel approaches zero as the independent variable increases or decreases 
without bound, whereas the Tricube and Epanechnikov kernels are identically zero 
outside of the interval [-1,1]. Thus all three functions have the characteristic shape of a 
single-peaked infection response with a common pre- and post-infection baseline. 
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The parameters of these functions correspond to aspects of the infection response 
that are typically of focal interest in MC experiments. Consider for instance the Gaussian 
kernel, defined by the function  
𝐾(𝑡) = (√2𝜋𝜎)
−1
𝑒𝑥𝑝 (
𝑡−𝜇
2𝜎
)
2
       (1.5) 
Here 𝜇 represents the time to peak response and 𝜎 can be interpreted as a measure 
response duration. By replacing the normalizing constant (√2𝜋𝜎)
−1
 with a third 
parameter I we obtain a measure of the peak response intensity. By incorporating a 
vertical shift parameter B we add the capability of modeling responses with nonzero 
baseline values, such as body temperatures. Thus we can modify the basic Gaussian 
kernel to obtain a function that directly models the most salient features of the infection 
response. 
𝐾(𝑡) = 𝐵 + 𝐼 𝑒𝑥𝑝 (
𝑡−𝜇
2𝜎
)
2
        (1.6) 
Figure 1.8. Gaussian, Tricube and Epanechnikov kernel functions 
One advantage of a compact kernel function such as the tricube is that the 
endpoints of the interval on which it takes nonzero values provide direct estimates of the 
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timing of response onset and recovery. By allowing for rescaling of both the time and 
response variables, we obtain a basic, symmetric tricube kernel response function (1.7). 
We explore several variations and extensions of these infection response functions. 
𝐾(𝑡) = 𝐵 + 𝐼 (1 + |
𝑡−𝑝
𝑠
|
3
)
3
        (1.7) 
In general, the choice of kernel is an aspect of model specification that the data 
analyst must decide upon.  The best kernel for the application depends on the shape of the 
peaked response as well as the desirability of compactness.  Overall, however, we found 
that the results were not particularly sensitive to choice of kernel for the applications we 
considered.  For this reason we do not extensively explore the choice of kernel in this 
dissertation. Instead, we give examples of the use of each kernel at various places in the 
dissertation: Gaussian kernels are employed in chapters 2 and 3, and a tricube kernel is 
used for the viral load modeling of chapter 4. Clearly there are other possible choices of 
functions for modeling the infection response trajectories but in this dissertation we 
restrict our attention to kernel functions. 
1.6.  SCOPE AND OUTLINE OF DISSERTATION 
 Chapter 1 establishes the importance of EI studies for research, epidemiology and 
prevention of infectious diseases. Several case studies illustrate the nature of longitudinal 
EI data. Traditional approaches to the analysis of this type of data are discussed and an 
alternative approach is suggested based on nonlinear hierarchical statistical models.   
 Chapter 2 considers the case of a symmetric transient response variable, that is, a 
variable that can adequately be approximated by a symmetric mean response function. 
We introduce a version of the normal-errors NLHM that can be fit using standard 
procedures available in several commonly used statistical packages.  We present a 
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simulation experiment comparing the performance of our Gaussian nonlinear mixed 
model with RM-ANOVA with respect to bias and precision of parameter estimation, 
power and Type I error control. Finally we provide an illustrative application to the 
equine arteritis virus data from § 1.3.1.  
Many responses will not be adequately modeled by a symmetric function. In 
Chapter 3 introduces a version of the normal-errors NLHM model suitable for modeling 
an asymmetric infection response. We discuss several reasons for preferring to implement 
this model as a Bayesian NLHM rather than a nonlinear mixed model. We illustrate the 
asymmetric Bayesian NLHM using the equine arteritis virus data from § 1.3.1. 
Frequently in MC experiments involving viral pathogens, the focus is the time 
course of the viral load in blood, feces or other fluids or excreta. For several reasons the 
normal-errors NLHM from Chapters 2 and 3 is not appropriate for modeling viral load. 
For the individuals in such experiments, viral load will be exactly zero at all observation 
times prior to inoculation. For those in whom the virus is completely cleared, viral load 
will return to exactly zero. During infection, however, viral load can be viewed as 
fluctuating randomly about some systematic trajectory. Thus the constant variance 
assumption is clearly violated. Further, because viral loads are nonnegative it makes no 
sense to model a subject’s viral load at each time point as a normal random variable. 
Finally, during infection it may happen the variability in viral load increases as the mean 
viral load increases. In Chapter 4 we propose an NLHM in which the viral load at each 
time point is modeled as a Poisson random variable with mean given by a compact kernel 
function. Because the variance of a Poisson random variable is equal to its mean, when 
the mean viral load is equal to zero (i.e. pre-onset or post-recovery) the variance will be 
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also. Similarly, when the mean viral load is positive (i.e. during infection) the variance 
will be positive, and the variance will increase with the mean. We illustrate the viral load 
NLHM using the rhinovirus data from § 1.3.2 and the influenza data from § 1.3.3. 
1.7. ETHICAL CONSIDERATIONS IN EI STUDIES 
 Despite their obvious potential benefits for the study of infectious diseases, EI 
studies in both humans and animal models raise a host of ethical concerns.  There have 
been numerous instances of ethically questionable practices involving the use of human 
subjects in infectious disease research (Zenilman 2013; Comfort 2009; Krugman 1986).  
In the United States, ethical guidelines for research involving human subjects have been 
established by the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research and summarized in its Belmont Report (1979).  The 
National Institutes of Health have published a framework for evaluating the ethical 
aspects of infection-inducing challenge experiments (Miller and Grady 2001). In the 
United Kingdom, the Academy of Medical Sciences has published the report Microbial 
Challenge Studies in Human Volunteers which provides recommendations and guidance 
to ensure the safe and ethical conduct of MCE’s involving human volunteers (2005).  The 
ethics of EI studies continue to be vigorously debated. Michetti has offered the following 
eloquent summary.  
Challenge experiments have been an important method of studying the 
pathogenesis of many infectious diseases and of evaluating initial efficacy of 
vaccines before large scale field tests are conducted. In challenge experiments, 
infections are deliberately induced under carefully controlled and monitored 
conditions to healthy research volunteers. Induced infections are usually either 
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self-limiting or can be fully treated within a short period of time. Because 
physicians should be dedicated to alleviating disease and avoiding harm to 
patients, this type of experiment may cause uncomfortable symptoms and evoke 
serious moral concerns. It should be appreciated however that clinical research 
commonly involves risks to subjects that are not outweighed by medical benefits 
but are justified by the potential to acquire new knowledge.  In that regard, 
infection inducing challenges are not necessarily more ethically problematic than 
phase I trials aimed at determining maximum tolerated doses of medications. Like 
any clinical research, challenge experiments should be conducted by competent 
investigators according to sound protocols that incorporate appropriate safeguards 
to ensure the safety of volunteers. Because these experiments may provide 
valuable information that might not be otherwise obtained, lead to novel 
therapies, or speed up vaccine development that will ultimately spare morbidity or 
death from infectious diseases and reduce exposure of large groups in field trials, 
challenge experiments may be justified. However, the scientific rationale should 
be carefully examined for any given pathogen and model. When such a rationale 
exists, then the question of risks and discomforts should be addressed (Michetti 
2004). 
 For experiments involving animal subjects, the counterpart to the Institutional 
Review Board (IRB) is the Institutional Animal Care and Use Committee (IACUC). The 
IACUC has its origins in the Animal Welfare Act passed by the U.S. Congress in 1966. 
Today in the U.S. an IACUC is required of all institution that uses animals in federally 
funded research. Functions of the local IACUC include review of research protocols and 
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evaluation of the care and use of animals (Anderson 2007). A key resource for IACUC’s 
is the Guide for the Care and Use of Laboratory Animals, which was published in 1963 
by a group of veterinarians known as the Animal Care Panel (Barthold et al. 2011). 
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CHAPTER TWO 
 
A nonlinear mixed model for a single-peaked, symmetric response 
 
2.1. INTRODUCTION 
 
 Some quantities of interest in the response to an infection, such as body 
temperature and lymphocyte counts, fluctuate around a natural baseline value when an 
individual is not experiencing infection. The natural baseline level may vary slightly from 
one individual to the next. Furthermore, in the infected state, although the mean response 
level changes over time the variation about the mean tends to remain relatively consistent 
(e.g. Figure 2.2). The normal-errors model introduced in Chapter 1 will often be 
appropriate in such cases. 
This chapter has three primary aims. First, we present a method for analyzing this 
type of longitudinal response data from experimental infection studies using a nonlinear 
mixed model (NLMM) that is straightforward to implement in popular statistical software 
packages. Second, we illustrate via Monte Carlo simulation the gains in accuracy, 
precision and power that this method provides over the traditional method of choice, RM-
ANOVA. Third, we illustrate the application of the model to data from an actual EI 
study. 
2.2.  NORMAL-ERRORS MODEL FOR A SYMMETRIC RESPONSE 
Suppose that infection responses for 𝑛  individuals are sampled on multiple 
occasions. Let 𝑚𝑖  represent the number of measurement occasions for individual 𝑖 . 
(Often in experimental infection studies 𝑚𝑖 is constant across individuals, but we do not 
assume it here.)  Let 𝑗 index the sampling times 𝑡1, 𝑡2,⋯ , 𝑡𝑚𝑖 for individual 𝑖. Denote the 
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responses for individual 𝑖 as 𝑦𝑖1, 𝑦𝑖2,⋯ , 𝑦𝑖𝑚𝑖. We model the individual response profiles 
with the modified Gaussian function (1.6).   
Level 1 (model of intra-individual variability) 
𝑦𝑖𝑗~𝑁(𝜇𝑖𝑗 , 𝜎
2)         (2.1) 
𝜇𝑖𝑗 =  𝐵𝑖 + 𝐼𝑖𝑒𝑥𝑝 [− (
𝑡−𝑝𝑖
2𝑠𝑖
)
2
]        (2.2) 
 
Here 𝐵𝑖 represents the baseline response level for individual 𝑖, 𝑝𝑖 the time to peak 
response, and 𝐼𝑖  the peak response intensity. 𝑠𝑖  can be interpreted as a measure of 
response duration. A closely related, but more interpretable, measure of response duration 
is the full width at half maximum response (FWHM), given by 𝐹𝑊𝐻𝑀𝑖 = 𝑠𝑖√2ln2. This 
is the width of the response curve when the response is halfway between baseline and 
peak intensity. 
To simplify the notation for Level 2 of the model, we collect the response parameters 
for individual 𝑖, into a vector 
𝜷𝑖 = [𝐵𝑖, 𝐼𝑖 , 𝑝𝑖 , log (𝑠𝑖)]
𝑇 .         (2.3) 
The scale parameter 𝑠𝑖 is modeled on the log scale to restrict its range to the positive 
real numbers. Now suppose that each individual belongs to one of two groups indexed by 
𝑔 ∈ {1,2}, and that individual i belongs to group 𝑔. For each group 𝑔 define a population 
parameter vector, which is assumed to give rise to the individual response vectors for 
members of group 𝑔, as  
𝜷(𝑔) = [𝐵(𝑔), 𝐼(𝑔), 𝑝(𝑔), log (𝑠(𝑔))]
𝑇
.       (2.4) 
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Finally let 𝜎
𝐵(𝑔)
2 , 𝜎
𝐼(𝑔)
2 , 𝜎
𝑝(𝑔)
2 , 𝜎
log 𝑠(𝑔)
2  and denote the variances of the corresponding 
components of 𝜷(𝑔). Then we specify the mechanism for the inter-individual response 
variability as follows. 
Level 2 (model of inter-individual variability) 
𝜷𝑖 = 𝜷
(𝑔) + 𝒃𝑖         (2.5) 
𝒃𝑖~𝑁(0,𝑫
(𝑔)), where 𝑫(𝑔) = diag (𝜎
𝐵(𝑔)
2 , 𝜎
𝐼(𝑔)
2 , 𝜎
𝑝(𝑔)
2 , 𝜎
log 𝑠(𝑔)
2 )   (2.6) 
A diagonal structure for 𝑫(𝑔) is specified because, due to the modest sample sizes 
typical of EI studies, there is usually an insufficient number of individuals to estimate a 
full 4 by 4 covariance matrix.   
If we had reason to believe that the variance structure were the same in both groups 
then we could specify instead 
𝒃𝑖~𝑁(0,𝑫), where 𝑫 = diag(𝜎𝐵
2, 𝜎𝐼
2, 𝜎𝑝
2, 𝜎log 𝑠
2 )     (2.7) 
This is the approach taken in the illustrative example in Section 2.4. 
2.2.1. Implementation as a nonlinear mixed model 
 The model (2.1)-(2.6) can be implemented as a nonlinear mixed model using 
widely available statistical computing systems including PROC NLMIXED (Nonlinear 
Mixed Models) in SAS, the ‘nlme’ (Linear and Nonlinear Mixed Effects Models) 
package in R, and numerous others. 
2.3. SIMULATION 
 In order to assess the performance of the normal-errors NLMM relative to 
traditional approaches to modeling experimental infection data, we performed a Monte 
Carlo simulation experiment. In the one-sample setting we compared the accuracy and 
precision of parameter estimates for the normal-errors NLHM and the one-way RM-
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ANOVA, and we computed the coverage rates of estimated confidence intervals for the 
parameter estimates from the former. (As we will see in §2.3.2, it is possible in RM-
ANOVA to define ad hoc quantities analogous to the components of 𝜷(𝑔) in the NLMM. 
However RM-ANOVA does not provide confidence intervals for those quantities so it is 
not possible to assess CI coverage for them.) In the two-sample setting we compared 
Type I error control and power for the normal-errors NLMM and the two-way RM-
ANOVA. 
2.3.1.  Data-generating models 
 We explored cases where the functional form of the response trajectories is 
correctly specified, and also cases where it is not. For the former cases, we first simulated 
true parameter vectors 𝜷𝑖 for each individual subject as specified in (2.5)-(2.6), and then 
we simulated response profiles for those individuals according to (2.1)-(2.2).   
To simulate incorrect specification of the functional form of the responses, we 
generated data from a normal-errors model with a parabolic response function (instead of 
Gaussian) as summarized in (2.8)-(2.11).  
Level 1 (model of intra-individual variability) 
𝑦𝑖𝑗~𝑁(𝜇𝑖𝑗 , 𝜎
2)         (2.8) 
𝜇𝑖𝑗 =  { 
𝑎𝑖(𝑡𝑗 − ℎ𝑖)
2 + (𝐵𝑖 − 𝑘𝑖) if  |𝑡𝑗 − ℎ𝑖| ≤ √
𝑘𝑖
𝑎𝑖
0 otherwise
     (2.9) 
 
Level 2 (model of inter-individual variability) 
𝜷𝑖 = 𝜷
(𝑔) + 𝒃𝑖         (2.10) 
𝒃𝑖~𝑁(0,𝑫
(𝑔)), where 𝑫(𝑔) = diag(𝜎
𝐵(𝑔)
2 , 𝜎
𝑘(𝑔)
2 , 𝜎
ℎ(𝑔)
2 , 𝜎
𝑎(𝑔)
2 )   (2.11) 
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 According to this data model, at the individual level, for time points in the interval 
[ℎ𝑖 ±√𝑘𝑖 𝑎𝑖⁄ ] the mean response follows a parabolic trajectory. For time points outside of 
this interval, the mean response is equal to 𝐵𝑖 . The population parameters 𝐵, ℎ and 𝑘 
correspond, respectively, to 𝐵, 𝑝 and 𝐼 in (2.3) with 𝑘 = −𝐼. The parameter 𝑎 governs the 
spread of the parabolic response.  Although 𝑎 itself has no direct relationship with 𝑠 in 
(2.3), we can directly compare the estimation of response duration by comparing 𝐹𝑊𝐻𝑀, 
which for the parabolic response function equals √2𝑘 𝑎⁄ . 
2.3.2.  One-sample simulation: method 
 In the one-sample setting we compared the performance of the normal errors 
NLHM with 𝑔 = 1 and the one-way RM-ANOVA model. The latter can be expressed as 
in (2.12)-(2.14), with 𝜇 representing the fixed population mean, 𝜋𝑖 a random effect for 
subject 𝑖  that does not change with time, and 𝜏𝑗  a fixed effect at time point 𝑗  that is 
common to all subjects. 
 𝑦𝑖𝑗 = 𝜇 + 𝜋𝑖 + 𝜏𝑗 + 𝜀𝑖𝑗       (2.12) 
𝜋𝑖~𝑁(0, 𝜎𝜋
2)          (2.13) 
𝜀𝑖𝑗~𝑁(0, 𝜎𝜀
2)         (2.14) 
The focus of the one-sample simulation was to compare the accuracy and 
precision of estimation of population/fixed effects. We examined four scenarios which 
are described in detail below. For each scenario we randomly generated 1,000 data sets 
from the appropriate data model (i.e. Gaussian or parabolic). The normal-errors NLMM 
(2.1)-(2.6) and one-way RM-ANOVA models (2.12)-(2.14) were then fit to each 
simulated data set. 
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The means of the population baseline, intensity, time-to-peak and duration 
estimates over the 1,000 simulated data sets were calculated for both models, along with 
the bias, variance and mean squared error (MSE) for each of the means. For the normal-
errors NLHM these quantities are directly estimated by the model. For RM-ANOVA, we 
must adopt ad hoc definitions for analogous quantities. The population baseline was 
taken to be the estimated response at the first time point, i.e. the estimated intercept. Peak 
response intensity was taken to be the difference between the largest estimated mean 
response and the baseline. Time to peak response was taken as the time point at which the 
group mean peak intensity was observed. FWHM was calculated by locating the time 
point on either side of the peak time where the estimated response was nearest in absolute 
value to one-half of the estimated peak intensity, and then taking the difference between 
those two times.  
We also compared the mean standard errors (𝑆𝐸̅̅̅̅ ) over the 1,000 data sets for the 
peak response intensity and FHWM estimates. These estimated standard errors are 
readily extracted from the fitted normal-errors NLMM. For RM-ANOVA, these  
quantities do not arise naturally from the model and can only be derived from the 
simulated data. Specifically, for RM-ANOVA, 𝑆𝐸̅̅̅̅ ?̂?  was taken to be the standard error of 
the estimated mean at the first time point, and 𝑆𝐸̅̅̅̅ 𝐼  was taken to be the standard error of 
the estimated mean at the time point where the peak response was observed. 
Model fitting for the normal-errors NLMM was accomplished with the ‘nlme’ 
package in R (R core team 2012). Initial parameter estimates for ‘nlme’ were set to their 
true values from the data generating model. The RM-ANOVA model (2.12)-(2.14) was 
fitted via the lme() function in R. 
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The default data-generating parameters, unless otherwise specified, were set as 
follows. 
Level 1 (model of intra-individual variability) 
 𝜎 =  5          (2.15) 
Level 2 (model of inter-individual variability) 
𝜷 = [20,30, 50, log (3)]𝑇  i.e. 𝐵 = 20, 𝐼 = 30, 𝑝 = 50, 𝑠 = 3  (2.16) 
𝑫 = diag(9,25, 4, 0.0625)  i.e. 𝜎𝐵 = 3, 𝜎𝐼 = 5, 𝜎𝑝 = 2, 𝜎𝑠 = 0.25  (2.17) 
The default data collection schedule was every fifth day between days 0 and 40, 
then every second day between days 42 and 60, then every fifth time point again between 
days 65 and 100. This simulates the approach typically taken in experimental infection 
studies, where sampling is more intensive during the period when the response is 
expected to occur, and less frequent outside of that interval. We denote this sampling 
schedule by a vector 𝒕0  to distinguish it from alternate schedules that were also 
considered. 
𝒕0 = [0,5,⋯ , 35, 40, 42,⋯ , 58, 60, 65,⋯ , 100]
𝑇     (2.18) 
2.3.3.  One-sample simulation: results 
Effect of sample size on parameter estimation 
We simulated sample sizes of n = 5, 15 and 30 subjects while holding the true 
population response parameters constant as in (2.15)-(2.17) and the sampling schedule as 
in (2.18) Results are summarized in Table 2.1. Several points are noteworthy. 1) The 
parameter estimates from the NLMM are more precise at all three sample sizes, with 
relative efficiencies ranging from 1.5 to 25.9 in favor the NLMM. The difference in 
efficiency was greatest when estimating FWHM, a measure of response duration. The 
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efficiency advantage persisted at larger sample sizes. At the smallest sample size (n=5), 
neither model precisely estimated intensity (I), but NLMM was nevertheless 2.2 times 
more efficient than RM-ANOVA. 2) RM-ANOVA underestimates intensity between 
13% and 18%, depending on sample size, and overestimates duration by 21%. 
Furthermore, neither bias diminishes as sample size increases, and the underestimation of 
intensity actually increases. This demonstrates that there is a systematic bias in the 
estimation of response intensity and duration by RM-ANOVA. 3) Both models estimate 
baseline and time to peak without bias at all three sample sizes, though again the NLMM 
estimates have uniformly greater precision. 4) For n=5, confidence interval coverage 
rates for population parameters in the NLMM were well below the nominal rate of 95% 
for, but for n=30 coverage was nominal or nearly so. The low coverage rates at small 
sample sizes are due largely to the fact that standard error estimates for the population 
parameters in the NLMM are conditional upon the variance component estimates. Thus, 
the standard error estimates do not reflect the uncertainty in the variance component 
estimates. 5) For RM-ANOVA, the average estimated standard error for the population 
baseline was more than double the average for NLMM at all three sample sizes, and the 
average estimated standard error for the population peak intensity was approximately 1.6 
times larger.    
Effect of sampling intensity on parameter estimation 
 Next we fixed the number of subjects at n=10 while varying the sampling 
schedule. We compared two schedules with similar numbers of total observations but 
different intensities: every third day over the entire study period and every second day 
within the true response interval but every fourth day outside the true response interval 
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We denote these two schedules by the vectors 𝒕333 and 𝒕424, which include 34 and 33 
sampling occasions respectively. 
𝒕333 = [0,3, 6,⋯ , 93, 96, 99]
𝑇       (2.19) 
𝒕424 = [0,4, 8, ⋯ , 36, 38, 40,⋯ , 92, 96, 100]
𝑇     (2.20) 
 The MSE’s in Table 2.2 show that estimation of peak intensity and duration were 
noticeably better for both models under 𝒕424 , and estimation of time to peak was 
improved for RM-ANOVA. Relative efficiencies still strongly favored the NLMM. We 
revisit the question of sampling intensity and schedule in Chapter 4. 
Effect of inter-individual response variability on parameter estimation 
 Reports on experimental infection studies often mention considerable variability 
in the individual response trajectories, but the effect of this variability on the estimation 
of response parameters is rarely addressed.  We analyzed the effect of inter-individual 
variation in the time to peak response. The number of individuals was held constant at 
N=15 and the sampling schedule at 𝒕0 (2.18) while σp was doubled from 2, as in (2.17), 
to 4. Results are summarized in Table 2.3. Increasing variability in the time to peak 
response negatively affects parameter estimation in both the NLMM and RM-ANOVA. 
However the former is far more robust to the increase, as can be seen by comparing the 
relative efficiencies of the parameter estimates for σp = 2 and σp = 4. In particular, the 
doubling of σp results in a doubling of the underestimation of peak intensity for RM-
ANOVA (from -4.8 to -11.0) and a tripling of the overestimation of FWHM (from 1.4 to 
4.4). 
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Effect of incorrect response function specification on parameter estimation 
 Finally we examined performance of the NLMM (2.1)-(2.6) when the true 
response function is not Gaussian. To simulate the performance of the NLMM when 
correctly specified, the data were generated from the same model (2.1)-(2.6).  To 
simulate performance when the response function is incorrectly specified, the data were 
generated from the parabolic data model in (2.8)-(2.11) with the following parameters. 
Level 1 (model of intra-individual variability) 
𝜎 =  5          (2.21) 
Level 2 (model of inter-individual variability) 
𝜷 = [20,−30, 50,−1.2]𝑇  i.e. 𝐵 = 20, 𝑘 = −30, ℎ = 50, 𝑎 = −1.2  (2.22) 
𝑫 = diag(9, 25, 4, 0.04)  i.e. 𝜎𝐵 = 3, 𝜎𝑘 = 5, 𝜎ℎ = 2, 𝜎𝑎 = 0.2  (2.23) 
The value of 𝑎 in (2.23) for the parabolic response function was chosen so as to 
make the true FWHM the same as for the Gaussian response. Thus, the Gaussian and 
parabolic response functions are essentially identical with respect to baseline, timing of 
peak, peak intensity and FWHM. However the Gaussian is considerably wider in the tails 
and slightly narrower near the peak. The default sampling schedule 𝒕0 (2.18) was used in 
both cases. Results are summarized in Table 2.4. 
Comparing the estimated relative efficiencies we see that when the true 
underlying response function was parabolic rather than Gaussian, the NLMM was still 
much more efficient than RM-ANOVA. 
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Table 2.1.  Effect of number of subjects on parameter estimation in normal-errors NLMM and one-way RM-ANOVA 
 n=5 n =15 n =30 
 
Parameter 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
B 20.0 20.0 - 20.0 20.0 - 20.0 20.0 - 
  Bias -0.03 (0.05) -0.02 (0.08) - 0.02 (0.03) 0.02 (0.05) - -0.02 (0.02) 0.0 (0.04) - 
  Variance 2.2 6.7 - 0.7 2.3 - 0.4 1.2 - 
  MSE 2.2 6.7 3.0 0.7 2.3 3.3 0.4 1.2 3.0 
  CI coverage 86% - - 93% - - 95% - - 
I 30.1 26.1 - 30.3 25.2 - 30.3 24.9 - 
  Bias 0.14 (0.09) -3.9 (0.13) - 0.32 (0.05) -4.8 (0.08) - 0.32 (0.04) -5.1 (0.06) - 
  Variance 8.0 17.5 - 2.6 6.0 - 1.4 3.5 - 
  MSE 8.0 32.9 2.2 2.7 28.8 2.3 1.5 29.4 2.5 
  CI coverage 87% - - 92% - - 94% - - 
𝑝 50.0 50.1 - 50.0 50.0 - 50.0 50.0 - 
  Bias 0.0 (0.01) 0.07 (0.04) - 0.02 (-0.01) 0.01 (0.02) - -0.01 (0.01) -0.03 (0.02) - 
  Variance 1.0 2.0 - 0.3 0.7 - 0.15 0.23 - 
  MSE 1.0 2.0 2.0- 0.3 0.7 2.3 0.15 0.23 1.5 
  CI coverage 86% - - 93% - - 92% - - 
FWHM 7.0 8.5 - 7.0 8.5 - 7.0 8.4 - 
  Bias -0.02 (0.02) 1.5 (0.09) - -0.05 (0.01) 1.4 (0.03) - -0.05 (0.01) 1.3 (0.03) - 
  Variance 0.34 8.8 - 0.11 1.1 - 0.06 0.7 - 
  MSE 0.34 10.9 25.9 0.11 3.0 10.0 0.06 2.3 11.7 
  CI coverage 92% - - 92% - - 92% - - 
          
𝑆𝐸̅̅̅̅ 𝐵 1.3 (0.01) 3.2 (0.01) - 0.8 (0.0) 1.9 (0.0) - 0.6 (0.0) 1.3 (0.0) - 
𝑆𝐸̅̅̅̅ 𝐼 2.5 (0.03) 4.1 (0.02) - 1.5 (0.01) 2.4 (0.01) - 1.1 (0.0) 1.7 (0.0) - 
B represents the population mean baseline level; I represents the population mean peak response intensity; 𝑝 represents the population mean time to 
peak response; and FWHM represents the population mean full width at half maximum, which is a measure of the duration of the infection response. 
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Table 2.2.  Effect of sampling intensity on parameter estimation in NLMM 
and one-way RM-ANOVA 
Parameter 
Sampling schedule 
𝒕333
 𝒕424
 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
𝐵 20.0 20.0 - 20.0 20.1 - 
  Bias -0.07 (0.03) -0.03 (0.06) - 0.02 (0.03) 0.09 (0.06) - 
  Variance 0.98 3.5 - 0.94 3.4 - 
  MSE 0.99 3.5 3.5 0.94 3.4 3.8 
𝐼 30.5 24.7 - 30.3 25.4 - 
  Bias 0.54 (0.07) -5.3 (0.09) - 0.28 (0.06) -4.6 (0.09) - 
  Variance 4.8 8.8 - 4.0 9.0 - 
  MSE 5.1 36.9 7.2 4.1 30.4 7.4 
𝑝 50.0 50.2 - 50.0 50.0 - 
  Bias -0.01 (0.02) 0.21 (0.04) - 0.01 (0.02) 0.03 (0.03) - 
  Variance 0.44 1.8 - 0.48 1.1 - 
  MSE 0.44 1.8 4.1 0.48 1.1 2.3 
𝐹𝑊𝐻𝑀 7.0 8.9 - 7.0 8.5 - 
  Bias -0.07 (0.02) 1.8 (0.06) - -0.04 (0.01) 1.4 (0.04) - 
  Variance 0.24 3.9 - 0.15 1.5 - 
  MSE 0.25 7.2 28.9 0.16 3.5 21.9 
       
𝑆𝐸̅̅̅̅ 𝐵 0.9 (0.01) 2.1 (0.0)  0.93 (0.01) 2.2 (0.01)  
𝑆𝐸̅̅̅̅ 𝐼 2.0 (0.01) 2.6 (0.01)  1.85 (0.01) 2.8 (0.01)  
B represents the population mean baseline level; I represents the population mean peak response intensity; 𝑝 
represents the population mean time to peak response; and FWHM represents the population mean full width 
at half maximum, which is a measure of the duration of the infection response. 
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Table 2.3.  Effect of variability in time to peak response on parameter 
estimation in one-sample NLMM and one-way RM-ANOVA 
 𝜎𝑝 = 2 𝜎𝑝 = 4 
 
Parameter 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
B 20.0 20.0 - 20.1 20.0 - 
  Bias 0.02 (0.03) 0.02 (0.05) - 0.14 (0.03) -0.01 (0.05) - 
  Variance 0.7 2.3 - 0.74 2.2 - 
  MSE 0.7 2.3 3.3 0.8 2.2 2.8 
I 30.3 25.2 - 28.9 19.0 - 
  Bias 0.32 (0.05) -4.8 (0.08) - -1.13 (0.08) -11.0 (0.1) - 
  Variance 2.6 6.0 - 7.0 8.1 - 
  MSE 2.7 28.8 10.7 8.3 128.2 15.4 
𝜇 50.0 50.0 - 49.9 49.9 - 
  Bias 0.02 (-0.01) 0.01 (0.02) - -0.06 (0.04) -0.1 (0.1) - 
  Variance 0.3 0.7 - 1.3 3.7 - 
  MSE 0.3 0.7 2.3 1.3 3.7 2.8 
FWHM 7.0 8.5 - 7.1 11.5 - 
  Bias -0.05 (0.01) 1.4 (0.03) - -0.01 (0.01) 4.4 (0.07) - 
  Variance 0.11 1.1 - 0.22 4.7 - 
  MSE 0.11 3.0 27.3 0.22 24.4 111.0 
       
𝑆𝐸̅̅̅̅ 𝐵 0.8 (0.0) 1.9 (0.0) - 0.8 (0.0) 2.2 (0.0) - 
𝑆𝐸̅̅̅̅ 𝐼 1.5 (0.01) 2.4 (0.01) - 2.1 (0.03) 2.9 (0.01) - 
B represents the population mean baseline level; I represents the population mean peak response intensity; 𝑝 
represents the population mean time to peak response; and FWHM represents the population mean full width 
at half maximum, which is a measure of the duration of the infection response. 
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Table 2.4.  Comparison of NLMM and RM-ANOVA when NLMM response function 
is incorrectly specified 
 Gaussian response Parabolic response 
 
Parameter 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
 
NLMM 
 
RM-ANOVA 
Relative 
efficiency 
B 20.0 20.0 - 19.8 20.1 - 
  Bias 0.02 (0.03) 0.02 (0.05) - -0.2 (0.03) -0.08 (0.05) - 
  Variance 0.7 2.3 - 0.7 2.3 - 
  MSE 0.7 2.3 3.3 0.7 2.3 3.3 
I 30.3 25.2 - 32.5 25.5 - 
  Bias 0.32 (0.05) -4.8 (0.08) - 2.5 (0.06) -4.5 (0.08) - 
  Variance 2.6 6.0 - 3.4 4.9 - 
  MSE 2.7 28.8 10.7 9.9 25.1 2.8 
𝜇 50.0 50.0 - 50.0 50.0 - 
  Bias 0.02 (-0.01) 0.01 (0.02) - -0.02 (0.02) 0.03 (0.02) - 
  Variance 0.3 0.7 - 0.3 0.6 - 
  MSE 0.3 0.7 2.3 0.3 0.6 2.0 
FWHM 7.0 8.5 - 6.2 7.9 - 
  Bias -0.05 (0.01) 1.4 (0.03) - -0.9 (0.01) 0.8 (0.03) - 
  Variance 0.11 1.1 - 0.1 0.8 - 
  MSE 0.11 3.0 27.3 0.9 1.5 1.7 
       
𝑆𝐸̅̅̅̅ 𝐵 0.8 (0.0) 1.9 (0.0) - 0.8 (0.0) 2.0 (0.0) - 
𝑆𝐸̅̅̅̅ 𝐼 1.5 (0.01) 2.4 (0.01) - 1.8 (0.01) 2.6 (0.01) - 
B represents the population mean baseline level; I represents the population mean peak response 
intensity; 𝑝 represents the population mean time to peak response; and FWHM represents the population 
mean full width at half maximum, which is a measure of the duration of the infection response. 
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2.3.4.  Two-sample simulation: method 
We next compared the performance of the normal errors NLMM model with 
𝑔 ∈ {1,2}, i.e. the two-sample NLMM model, with the two-way RM-ANOVA model. 
The latter can be expressed as follows, with 𝜇 representing a fixed population mean, 𝛾𝑔  a 
fixed effect for group 𝑔 that is common to all time points,  𝜏𝑗 a fixed effect at time point 𝑗 
that is common to all subjects, (𝛾𝜏)𝑔𝑗 a fixed effect unique to the members of group 𝑔 
that is specific to time 𝑗, and 𝜋(𝑖)𝑔 a random effect for subject 𝑖 within group 𝑔 that does 
not change with time. 
 𝑌𝑖𝑔𝑗 = 𝜇 + 𝛾𝑔 + 𝜏𝑗 + (𝛾𝜏)𝑔𝑗 + 𝜋𝑖(𝑔) + 𝜀𝑖𝑔𝑗      (2.24) 
𝜋𝑖(𝑔)~𝑁(0, 𝜎𝜋
2)        (2.25) 
 𝜀𝑖𝑔𝑗~𝑁(0, 𝜎𝜀
2)        (2.26) 
∑ 𝛾𝑔
2
𝑔=1 = 0, ∑ 𝜏𝑗
𝑚
𝑗=1 = 0, ∑ (𝛾𝜏)𝑔𝑗
2
𝑔=1 = 0, ∑ (𝛾𝜏)𝑔𝑗
𝑚
𝑗=1 = 0  (2.27) 
In (2.27), 𝑚 represents the final measurement occasion which, in the simulations, 
is the same for all individuals. The findings on parameter estimation from the one-sample 
simulation carry over to estimation in the two-sample setting. Our focus for the two-
sample case, therefore, was a comparison of power and Type I error control for testing 
the null hypothesis of no difference between the true group infection responses. For RM-
ANOVA this amounts to the hypothesis that the time-specific group effects are equal at 
all measurement occasions, i.e.  
𝐻0: (𝛾𝜏)1𝑗 = (𝛾𝜏)2𝑗  for all 𝑗       (2.28) 
We fit the two-sample RM-ANOVA model (2.24)-(2.27) and conducted the 
hypothesis test (2.28) using both the traditional approach, implemented in R by the 
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function aov() within the ‘stats’ package, and a mixed model approach using the R 
function lme() within the ‘nlme’ package, respectively. 
 For the NLMM (2.1)-(2.6) the hypothesis of no difference in the mean population 
infection responses can be expressed as 
𝐻0: 𝐼
(1) = 𝐼(2) and 𝑝(1) = 𝑝(2) and 𝑠(1) = 𝑠(2).     (2.29) 
 Following the recommendation of Pinheiro and Bates (2000) we tested this hypothesis 
via conditional F test. 
Data were generated for each group independently using the same process 
described for the one-sample simulation.  
2.3.5.  Two-sample simulation: results 
Type I error control for test of no difference in group responses 
 Response data for both groups were generated using the parameter values in 
(2.15)-(2.17) so that there was, in fact, no difference in the population infection 
responses. The experiment was repeated for group sizes ranging from N=5 to N=100 
individuals. At each sample size 1,000 data sets were generated using both the Gaussian 
response function (2.2) and the parabolic response function (2.9). The hypotheses (2.28) 
and (2.29) were tested as describe above and the proportion of Type I errors was 
computed for each method along with 95% Clopper-Pearson confidence intervals. Thus 
we examined the Type I error rates for NLHM and RM-ANOVA at six different sample 
sizes when the response function in the NLHM was correctly specified and when it was 
incorrectly specified. 
Results are summarized in Table 2.5. We consider first the case when the true 
response function was Gaussian. For larger sample sizes (n =15, n =30) the Type I error 
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rate was near the nominal rate for both NLMM and RM-ANOVA [aov() 
implementation). However for smaller sample sizes (n =5, n =10) the Type I error rate for 
RM-ANOVA was nearly twice the nominal rate and for NLMM it was two to three times 
higher.  When the true response function was parabolic, NLMM was not much affected. 
However RM-ANOVA fared slightly worse at all sample sizes.  
For the lme() implementation of RM-ANOVA, the rate remained two to three 
times above the nominal rate across all sample sizes from n=5 to n=100, irrespective of 
the true shape of the response function. 
Table 2.5.  Type I error rate by sample size for NLMM and RM-ANOVA 
 Gaussian data model Parabolic data model 
n NLMM RM-
ANOVA  
LMM NLMM RM-
ANOVA 
LMM 
5 0.15  
(0.13, 0.18) 
0.09  
(0.07, 0.11) 
0.13  
(0.10, 0.15) 
0.15  
(0.12, 0.17) 
0.11  
(0.09, 0.13) 
0.16  
(0.13, 0.18) 
10 0.10  
(0.08, 0.12) 
0.07  
(0.06, 0.09) 
0.15  
(0.12, 0.17) 
0.09  
(0.07, 0.11) 
0.09  
(0.07, 0.10) 
0.14  
(0.12, 0.16) 
15 0.09  
(0.07, 0.11) 
0.07  
(0.05, 0.08) 
0.12  
(0.10, 0.14) 
0.07  
(0.05, 0.08) 
0.08  
(0.06, 0.10) 
0.13  
(0.11, 0.15) 
30 0.08  
(0.06, 0.09) 
0.07  
(0.06, 0.09) 
0.15  
(0.13, 0.18) 
0.05  
(0.04, 0.07) 
0.08  
(0.06, 0.10) 
0.13  
(0.11, 0.16) 
50 0.06  
(0.04, 0.07) 
0.07  
(0.05, 0.08) 
0.13  
(0.11, 0.15) 
0.05  
(0.04, 0.07) 
0.09  
(0.07, 0.11) 
0.15  
(0.13, 0.17) 
100 0.05  
(0.04, 0.07) 
0.06  
(0.05, 0.08) 
0.13  
(0.11, 0.16) 
0.04  
(0.03, 0.05) 
0.08  
(0.06, 0.10) 
0.14  
(0.12, 0.17) 
 
Power to detect a true difference in group responses 
 To investigate the power of NLHM and RM-ANOVA to detect true differences in 
population infection responses between groups, we considered three scenarios: 
 𝐼(1) ≠ 𝐼(2), 𝑝(1) = 𝑝(2), 𝑠(1) = 𝑠(2)      (2.30) 
𝐼(1) = 𝐼(2), 𝑝(1) ≠ 𝑝(2), 𝑠(1) = 𝑠(2)      (2.31) 
𝐼(1) = 𝐼(2), 𝑝(1) = 𝑝(2), 𝑠(1) ≠ 𝑠(2)      (2.32) 
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 A 
 
B 
 
C 
 
Figure 2.1.  Population response curves for two-sample simulation. (A) Peak intensity: 
𝐼(1) = 30 vs. 𝐼(2) = 36. (B) Response duration: 𝑠(1) = 2.5 vs. 𝑠(2) = 3 [𝐹𝑊𝐻𝑀(1) = 5.9 
vs. 𝐹𝑊𝐻𝑀(2) = 7.1 days]. (C) Time to peak: 𝑝(1) = 49 vs. 𝑝(2) = 51 days. 
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As in the Type I error experiment we began with the true parameter values for 
both groups specified as in (2.15)-(2.17).  For scenario (2.30), we increased I(2) from 30 
to 36; for scenario (2.31) we decreased p(1)  to 49 and increased p(2)  to 51; and for 
scenario (2.32) we decreased s(1)  from 3 to 2.5, which is equivalent to decreasing 
FWHM(1) from 7.1 days to 5.9 days. The three scenarios are visualized in Figure 2.1. 
Table 2.6.  Effect of number of subjects on power to detect a true difference 
in response to infection in two-sample NLMM and two-way RM-ANOVA 
 Sample size 
Parameter and model n=5 n =15 n =30 
Peak intensity (𝐼) 
  NLHM 0.40 (0.37, 0.43) 0.64 (0.61, 0.67) 0.92 (0.90, 0.93) 
  RM-ANOVA – aov() 0.14 (0.12, 0.17) 0.23 (0.20, 0.26) 0.42 (0.40, 0.45) 
  RM-ANOVA – lme() 0.21 (0.18, 0.23) 0.35 (0.32, 0.38) 0.57 (0.54, 0.60)   
Response duration (𝐹𝑊𝐻𝑀) 
  NLHM 0.43 (0.40, 0.46) 0.71 (0.68, 0.73) 0.94 (0.92, 0.95) 
  RM-ANOVA  - aov() 0.10 (0.08, 0.12) 0.11 (0.09, 0.13) 0.19 (0.16, 0.21) 
  RM-ANOVA – lme() 0.18 (0.15, 0.20) 0.20 (0.18, 0.23) 0.32 (0.30, 0.35) 
Time to peak intensity (𝑝) 
  NLHM 0.39 (0.36, 0.42) 0.67 (0.64, 0.70) 0.91 (0.89, 0.92) 
  RM-ANOVA – aov() 0.37 (0.34, 0.40) 0.74 (0.71, 0.77) 0.96 (0.94, 0.97) 
  RM-ANOVA – lme() 0.45 (0.41, 0.48) 0.82 (0.79, 0.84) 0.97 (0.96, 0.98) 
 
For all scenarios we estimated the power of each method at three sample sizes 
(N=5, 15, 30). At each sample size 1,000 data sets were generated using both the 
Gaussian response function (2.2) and the parabolic response function (2.9). The 
hypotheses (2.28) and (2.29) were tested as described above and power was estimated as 
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the proportion of data sets for which the null hypothesis was correctly rejected, along 
with 95% Clopper-Pearson confidence intervals. The two data models correspond to 
correct and incorrect specification of the mean response function for the NLHM.   
Results are summarized in Table 2.6. We find that the NLMM, when correctly 
specified, has between two and six times the power of RM-ANOVA to detect a true 
difference in response duration or intensity at sample sizes ranging from n=5 to n =30.  
Interestingly, RM-ANOVA outperformed the NLMM by a modest amount for detecting a 
difference in time to peak. Misspecifying the response function as Gaussian when it was 
truly parabolic did not adversely affect power (Table 2.7). 
Table 2.7.  Effect of number of subjects on power to detect a true difference in response 
to infection in two-sample NLMM and two-way RM-ANOVA – NLMM mean response 
function incorrectly specified 
 Sample size 
Parameter and model n =5 n =15 n =30 
Peak intensity (𝐼) 
  NLHM 0.44 (0.41, 0.47) 0.73 (0.70, 0.76) 0.96 (0.95, 0.97) 
  RM-ANOVA – aov() 0.18 (0.15, 0.20) 0.36 (0.33, 0.39) 0.64 (0.61, 0.67) 
  RM-ANOVA – lme() 0.25 (0.22, 0.28) 0.47 (0.44, 0.50) 0.75 (0.73, 0.78) 
Response duration (𝐹𝑊𝐻𝑀) 
  NLHM 0.39 (0.35, 0.42) 0.67 (0.64, 0.70) 0.95 (0.93, 0.96) 
  RM-ANOVA – aov() 0.10 (0.08, 0.12) 0.14 (0.12, 0.16) 0.23 (0.21, 0.25) 
  RM-ANOVA – lme() 0.16 (0.14, 0.18) 0.24 (0.21, 0.26) 0.35 (0.32, 0.40) 
Time to peak intensity (𝑝) 
  NLHM 0.39 (0.35, 0.42) 0.62 (0.59, 0.65) 0.91 (0.89, 0.92) 
  RM-ANOVA – aov() 0.36 (0.33, 0.39) 0.77 (0.74, 0.79) 0.95 (0.94, 0.97) 
  RM-ANOVA – lme() 0.45 (0.41, 0.48) 0.83 (0.80, 0.85) 0.98 (0.97, 0.99) 
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2.4. ILLUSTRATIVE EXAMPLE 
Referring to the EAV case studies from Chapter 1, we compare the population 
febrile responses to the Bucyrus and Kentucky-84 strains of EAV. In the experiments by 
Go and Campos, core body temperature (CBT) was observed on days -7, -4 and -2 prior 
to inoculation and on days 0, 2, 4, 6, 8, 10, 12 and 14 post-inoculation (DPI). Go et al 
challenged eight mares with the Bucyrus strain whereas Campos et al challenged eight 
stallions with the KY-84 strain. Figure 4 presents the observed, subject-specific febrile 
response profiles for the two groups.  
Figure 2.2. Observed febrile response profiles for eight mares challenged with the 
Bucyrus strain of EAV, and eight stallions challenged with the Kentucky-84 strain 
All sixteen profiles display a single-peaked response with a common pre- and 
post-infection baseline body temperature. We modeled the febrile responses using the 
NLHM in (2.1)-(2.7) with 𝑔 ∈ {1,2}.  The estimate of 𝜎log (𝑠) was essentially zero, 
suggesting no need to include subject-specific scale parameters in the model. We refit the 
model with the scale parameters treated as purely fixed effects. Diagnostic checks did not 
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indicate any violations of distributional assumptions (see supplemental plots in Appendix 
A). The posterior estimates are summarized in Table 2.8. 
Table 2.8. Estimates of population febrile response parameters following challenge of 
eight mares with Bucyrus strain of EAV and eight stallions with KY-84 strain 
Bucyrus strain (mares) KY-84 strain (stallions) 
Parameter Estimate 95% CI Parameter Estimate 95% CI 
Population infection response parameters 
𝐵(1) 99.4 (99.1, 99.7) 𝐵(2) − 𝐵(1) -0.03 (-0.50, 0.43) 
𝐼(1) 3.3 (2.8, 3.8) 𝐼(2) − 𝐼(1) 1.3 (0.6, 2.0) 
𝑝(1) 6.3 (6.0, 6.6) 𝑝(2) − 𝑝(1) -0.6 (-1.1, -0.2) 
log (𝑠)(1) 0.86 (0.71, 1.02) log 𝑠(2) − log 𝑠(1) -0.05 (-0.24, 0.14) 
Variance components 
𝜎𝐵 0.33 (0.20, 0.56)    
𝜎𝐼 0.47 (0.22, 0.99)    
𝜎𝑝 0.23 (0.09, 0.57)    
𝜎 0.82 (0.75, 0.89)    
 
The population parameters characterize the mean response to inoculation with the 
Bucyrus strain of EAV in mares (superscript 𝑔 = 1) and the KY-84 strain in stallions 
(superscript 𝑔 = 2 ). (More precisely, they represent the mean infection response 
parameter values for the populations from which the samples were drawn. If the samples 
were selected at random from a well-defined population then the posterior means can be 
interpreted as estimates of the true mean values within the source population.) The 
estimates of baseline CBT differ by only 0.03 ℉ (-0.50, 0.43), as might be expected. The 
duration of fever was similar also, with the scale parameter estimates differing by -0.05 (-
0.24, 0.14) units on the log scale. This translates to a difference in FWHM of 0.3 (-0.8, 
1.2) days. However they differed with respect to peak fever intensity and time to peak 
fever. On average, in the stallions challenged with the KY-84 strain, the febrile response 
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peaked 0.6 (-1.1, -0.2) days earlier with a maximum intensity 1.3 (0.6, 2.0) degrees 
higher. The 95% confidence intervals suggest that the true differences in significantly 
different than zero. Figure 2.3 illustrates the population febrile response curves for the 
two groups. 
 
Figure 2.3. Population febrile response curves for mares challenged with the Bucyrus 
strain of EAV, and stallions challenged with the Kentucky-84 strain 
 Formally testing the hypothesis of no difference in population infection responses 
(2.29) with  a conditional F test, we find evidence in favor of rejecting [F=7.1, p=0.0001, 
df=(3,265)]. Furthermore, testing hypothesis (2.28) with the two-way RM-ANOVA 
model (2.24)-(2.26) leads to the same conclusion (F=4.3, p<0.0001).  
The variance component estimates quantify the extent to which individual febrile 
responses may vary about their group’s population response. Thus for example, for a 
particular mare from the source population inoculated with the Bucyrus strain of EAV, it 
would be quite unusual to observe a fever that peaked at less than 𝐼(1) − 1.96𝜎𝐼 = 2.4℉ 
above baseline CBT or at higher than  𝐼(1) + 1.96𝜎𝐼 = 4.2℉  above baseline. The 
estimates of 𝜎𝐵 and 𝜎𝑝 have similar interpretations. 
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2.5. DISCUSSION 
In this chapter we proposed a nonlinear mixed model (2.1)-(2.6) suitable for 
modeling a continuous, longitudinal response variable having normally distributed errors 
with constant variance across all measurement occasions. Example of such responses 
include quantities such as body temperature and lymphocyte counts. The model assumes 
that the systematic portion of the intra-individual response variation follows a Gaussian 
trajectory. Thus it is appropriate for situations in which the individual responses are 
approximately symmetric about a single peak. Implementation is straightforward using 
the NLMM framework (Lindstrom and Bates 1990, Davidian and Giltinan 1995) 
available in many standard software packages. 
We proposed this model as an alternative to RM-ANOVA, which has traditionally 
been the most commonly used method of analyzing longitudinal response data from EI 
studies. The primary difference between the two approaches is that RM-ANOVA treats 
the responses at each time point as if they were unrelated to one another, whereas the 
NLMM models the relationship among the responses across time points through 
individual mean response functions (2.2). One consequence is that in RM-ANOVA each 
additional measurement occasion increases by one the number of degrees of freedom 
used to estimate the model. By contrast, the number of degrees of freedom in estimating 
the NLHM does not depend on the number of time points observed.  We hypothesized 
that this difference would result in less efficient estimation of model parameters for RM-
ANOVA, particularly when the number of measurement occasions is large. Another 
advantage of the NLMM is that its parameters represent aspects of the infection response 
of inherent biological interest: baseline, time to peak response, peak intensity and 
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response duration. In RM-ANOVA such quantities can only be approximated by ad-hoc 
methods. 
2.5.1. Simulation: estimation 
We tested our primary hypothesis via Monte Carlo simulation experiments.  
Simulation results indicated that the NLHM substantially outperformed RM-ANOVA 
across a broad range of scenarios, and that under certain conditions the improvement can 
be enormous. We found estimation in the NLHM to be more precise than RM-ANOVA 
for all model parameters, and less biased for peak intensity and duration parameters.  
We also demonstrated the effect of increased inter-individual response variability 
on parameter estimation. It seems self-evident to us that, unless there is very little 
variation in the timing of the individual peaks, any approach that involves naïvely 
averaging a group of single-peaked response profiles in a pointwise manner will result in 
understated peak intensity and overstated response duration. When the individual peaks 
occur at different times the effect will be to dampen the estimate of the population peak 
intensity. Further, the occurrence of even a small number of responses of unusually long 
duration will give the appearance, under pointwise averaging, that the population 
response duration is longer than it truly is. This effect has been noted recently in an EI 
study by DeVincenzo and colleagues (2010). Specifically, in studying viral loads in 
subjects experimentally challenged with respiratory synctitial virus, they point out that 
when the individual viral load curves are naïvely averaged the breadth (duration) of the 
resulting population curves is misleadingly wide, and the magnitude (intensity) 
misleadingly low. (They attempted to correct for this effect by adjusting the individual 
viral load curves based on an arbitrary “incubation time”. Our method requires no such 
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ad-hoc adjustment.) Our simulation experiment confirmed that increasing variability in 
the time to peak response negatively affects parameter estimation in both the NLMM and 
RM-ANOVA, but that the former is far more robust to the increase. 
Finally, we explored the effect of incorrect specification of the mean response 
function on parameter estimation. We found that when the true underlying response 
function was parabolic rather than Gaussian, the NLMM was still considerably more 
efficient than RM-ANOVA. 
2.5.2. Simulation: type I error control and power 
When the number of subjects per group was 5, the Type I error rate for RM-
ANOVA was nearly twice the nominal rate and for NLMM it was three times the 
nominal rate. For 𝑛=10 the Type I error rate for NLMM was still twice nominal. These 
results suggest that experimental infection studies with small numbers of individuals per 
group – which appear to be the norm in the literature – are subject to higher-than-nominal 
Type I error rates, with either NLMM or RM-ANOVA. 
Our power analysis indicates that in certain scenarios the NLMM provides a large 
increase in power over RM-ANOVA with comparable Type I error control. In our 
simulation, in all scenarios the NLMM achieved 80% power to detect differences in 
response duration and peak intensity with somewhere between 15 and 30 subjects per 
group. By contrast, with 30 subjects per group RM-ANOVA achieved only 42% power 
for a true difference in peak intensity and 19% power for a true difference in response 
duration. 
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2.5.3. Illustrative example 
When applied to the EAV febrile response data, both the NLMM and RM-
ANOVA detected a significant difference in the mean population febrile response of 
mares challenged with the recombinant Bucyrus strain compared to the response of 
stallions challenged with the KY-84 strain. Judging from Figure 2.3, the essential 
difference between the febrile responses appears to be in intensity of the peak. For the 
simulated data the relative change in intensity was  
𝐼(2)−𝐼(1)
𝐼(1)
=
36−30
30
= 0.2, and for the 
febrile response data we can estimate  
4.6−3.3
3.3
= 0.39. In other words, in the febrile 
response data we were searching for a relative change that was twice the size of the 
relative change in the simulated data. In this case the change was large enough to be 
detected by either method.  
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CHAPTER THREE 
 
A Bayesian hierarchical model for a single-peaked, asymmetric infection response 
 
3.1.  INTRODUCTION 
 
In Chapter 2 we presented the normal-errors NLHM as an alternative to repeated 
measures analysis of variance (RM-ANOVA) for analyzing time course data from 
experimental infection studies. We demonstrated, via Monte Carlo simulation 
experiments, scenarios in which the NLHM provides more accurate and precise 
estimation of population parameters, and greater power for detecting group differences, 
than RM-ANOVA. Furthermore, at moderate-to-large sample sizes (N=15 or greater) it 
provides near-nominal Type I error control. 
Chapter 2 focused on the case of a symmetric response. The symmetric model 
was implemented as a nonlinear mixed model (NLMM) (Sheiner et al 1972, Lindstrom 
and Bates 1990, Davidian and Giltinan 1995, Vonesh and Chinchilli 1997). One 
attractive feature of this approach is the availability of several widely used software 
packages for fitting NLMM’s. However it is important to note that maximum likelihood 
estimation and inference for NLMM’s are based on asymptotic results which are not 
guaranteed to hold for the relatively small sample sizes typical of EI studies. 
In the present chapter we consider asymmetric responses within the context of the 
normal-errors NLHM. A Bayesian approach to model implementation is introduced in 
part to avoid the large-sample assumptions of the NLMM approach, but it proves to have 
several additional benefits which we discuss. 
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3.2.  NORMAL-ERRORS NLHM FOR AN ASYMMETRIC RESPONSE 
3.2.1. Modeling an asymmetric infection response 
In Chapter 2 we introduced a model for a symmetric infection response based on a 
Gaussian mean response function:  
𝑓(𝑡) =  𝐵 + 𝐼 ∗ 𝑒𝑥𝑝 [− (
𝑡−𝑝
2𝑠
)
2
]        (3.1) 
One way to extend this model to accommodate asymmetric responses is to replace 
(3.1) with a piecewise function consisting of two half-Gaussian curves that are given 
different scale parameters but constrained to meet at their peaks, as in (3.2). 
𝑓(𝑡) = {
𝐵 + 𝐼 ∗ 𝑒𝑥𝑝 [−
(𝑡−𝑝)2
2𝑙2
] , 𝑡 ≤ 𝑝
𝐵 + 𝐼 ∗ 𝑒𝑥𝑝 [−
(𝑡−𝑝)2
2𝑟2
] , 𝑡 > 𝑝
     (3.2) 
The interpretations of the parameters 𝐵, 𝐼 , and 𝑝  are unchanged. The scale 
parameters l and r can be interpreted, respectively, as measures of the duration of the 
onset and recovery phases of infection. If more interpretable measures of these quantities 
are desired, l and r are directly proportional to the half-widths at half-maximum intensity 
(HWHM): 𝐻𝑊𝐻𝑀𝑙 = 𝑙√2ln2 and 𝐻𝑊𝐻𝑀𝑟 = 𝑟√2ln2.  The full width at half-maximum 
intensity (FWHM) can be interpreted as an index of total response duration: 𝐹𝑊𝐻𝑀 =
𝐻𝑊𝐻𝑀𝑙 +𝐻𝑊𝐻𝑀𝑟 = (𝑙 + 𝑟)√2ln2 . Figure 3.1 demonstrates the flexibility of the 
piecewise half-Gaussian function to describe a wide range of response trajectories. Other 
applications of piecewise functions in nonlinear regression models have been described 
by Huisman (1993), Müller (1997) and Gössl (2001).  
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Figure 3.1. Response shapes accommodated by a piecewise Gaussian function 
3.2.2. Statement of the model 
We are now in a position to state the normal-errors NLHM for an asymmetric 
infection response, using a piecewise Gaussian kernel for the mean response function. 
Suppose that infection responses for 𝑛  individuals selected at random from a target 
population have been sampled on multiple occasions. For generality we allow the number 
of observations to vary among individuals and we denote by 𝑚𝑖 the number of sampling 
occasions for individual 𝑖. Let 𝑗 index the sampling times 𝑡1, 𝑡2,⋯ , 𝑡𝑚𝑖  for individual and 
denote the responses for individual 𝑖 as 𝑦𝑖1, 𝑦𝑖2,⋯ , 𝑦𝑖𝑚𝑖.    
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Level 1 (model of intra-individual variability) 
𝑦𝑖𝑗~𝑁(𝜇𝑖𝑗 , 𝜎
2)          (3.3) 
𝜇𝑖𝑗 =
{
 
 𝐵𝑖 + 𝐼𝑖𝑒𝑥𝑝 [−
(𝑡𝑗−𝑝𝑖)
2
2𝑙𝑖
2 ] , 𝑡𝑗 ≤ 𝑝𝑖
𝐵𝑖 + 𝐼𝑖𝑒𝑥𝑝 [−
(𝑡𝑗−𝑝𝑖)
2
2𝑟𝑖
2 ] , 𝑡𝑗 > 𝑝𝑖
 
       (3.4) 
Level 2 (model of inter-individual variability) 
𝜷𝑖 = 𝜷
(𝑔) + 𝒃𝑖         (3.5) 
𝒃𝑖~𝑁(0,𝑫
(𝑔)), where 𝑫(𝑔) = diag (𝜎
𝐵(𝑔)
2 , 𝜎
𝐼(𝑔)
2 , 𝜎
𝑝(𝑔)
2 , 𝜎
log 𝑙(𝑔)
2 , 𝜎
log 𝑟(𝑔)
2 ) (3.6) 
The scale parameters 𝑙𝑖 and 𝑟𝑖 are modeled on the log scale to restrict their ranges to 
the positive real numbers. As in Chapter 2, we assume that individual 𝑖 belongs to group 
𝑔, where 𝑔 ∈ {1,2}, and that 𝜷𝑖 and 𝜷
(𝑔) are defined as follows. 
𝜷𝑖 = [𝐵𝑖, 𝐼𝑖 , 𝑝𝑖 , log (𝑙𝑖), log (𝑟𝑖)]
𝑇 .        (3.7) 
𝜷(𝑔) = [𝐵(𝑔), 𝐼(𝑔), 𝑝(𝑔), log 𝑙(𝑔), log 𝑟(𝑔)]
𝑇
       (3.8) 
If there is reason to think that the inter-individual variability is not significantly 
different between the two groups then in 3.6 we can alternatively specify that 𝑫(𝑔) =
diag(𝜎𝐵
2, 𝜎𝐼
2, 𝜎𝑝
2, 𝜎log 𝑙
2 , 𝜎log𝑟
2 ). 
3.2.3. Bayesian implementation 
In principle the NLHM (3.3)-(3.8) may be implemented within either a frequentist 
or Bayesian framework. We pursued a Bayesian approach in part to avoid the large-
sample assumptions of the NLMM approach, but there are numerous additional benefits.  
Model specification is entirely under the control of the analyst. This can simplify 
diagnosis of the convergence problems that often arise in NLHM’s with small samples. It 
also provides finer control over the details of model specification than may be possible in 
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many off-the-shelf software packages. Furthermore, calculation of various secondary 
quantities of interest, such as credible intervals on mean response curves and timing of 
response onset and recovery, is straightforward.  
A Bayesian perspective considers the model parameters 𝜷, 𝜎 and 𝑫 not as fixed, 
unknown quantities, but as random variables with probability distributions. The 
investigator’s a priori knowledge about the likely values of these parameters is specified 
by prior distributions 𝑝(𝜷), 𝑝(𝜎) and 𝑝(𝑫). The joint posterior distribution of the model 
parameters is obtained via Bayes’ Theorem, which updates the prior based on the 
likelihood of the observed data obtained from the EI study (LeSaffre and Lawson 2012). 
Inference is then based on the resulting joint posterior distribution of 𝜷, 𝜎 and 𝑫.  
We specified uniform priors of the form (0,c) for the residual standard deviation 𝜎 
and for all standard deviation parameters in 𝑫, thus reflecting vague prior knowledge 
about their likely values. Gelman (2006) has recommended uniform priors of this form 
for the variance component parameters in hierarchical models over the more traditional 
choices of inverse Gamma and Wishart priors. For the population infection response 
parameters in 𝜷 we also specified uniform (0,c) priors for the scale parameters log 𝑙 and 
log 𝑟, the intensity parameter I, and the time to peak parameter 𝑝. Finally we specified a 
uniform (a,b) prior for the baseline parameter 𝐵. The constants a, b and c reflect bounds 
on the plausible population mean values. Gaussian priors with large variances are often 
used for population parameters in hierarchical models (LeSaffre and Lawson 2012). This 
would be a reasonable alternative to the uniform prior for the 𝐵, but not for the other 
infection response parameters. Note that another advantage of the Bayesian approach is 
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the ability to incorporate prior knowledge about the parameters, if available, into the 
model specification via informative prior distributions.   
All models were fit using R version 2.15 interfaced with JAGS through the 
R2JAGS package
 
(R core team 2012, Plummer 2003). 
3.3.  ILLUSTRATIVE EXAMPLES 
3.3.1.  Lymphocyte response to equine arteritis virus infection in horses 
Our first example references the case studies on equine arteritis virus (EAV) from 
Chapter 1. In the experimental infection study by Go et al (2011), lymphocyte counts 
were determined from blood samples collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 
42 days following challenge with a virulent, recombinant Bucyrus strain of EAV. In the 
original study there was a total of eight mares belonging to two groups, one with the in 
vitro susceptible CD3+ T cell phenotype and one with the resistant phenotype, and the 
purpose was to compare the time course of lymphocyte counts (and other responses) 
between the two groups. For the present example we ignore the group structure and 
consider the eight mares as a single sample. Figure 3.2 presents the observed, subject-
specific febrile response profiles for the two groups.  
All eight profiles suggest a single-peaked response with a common pre- and post-
infection baseline lymphocyte count, although the baseline level varies considerably 
among horses. Because the counts appear to be less variable during the response phase 
than during baseline when the individuals are not infected, we applied a square root 
transformation of the responses to stabilize the variance over the experimental period. We 
modeled the transformed lymphocyte responses using the asymmetric normal-errors 
NLHM in (3.3)-(3.6), with 𝑔 = 1. Satisfactory convergence was achieved with 75,000 
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MCMC iterations following 25,000 burn-in. Convergence diagnostics and supplemental 
plots are included in Appendix A. The posterior estimates are summarized in Table 3.1. 
Figure 3.2 Observed lymphocyte response profiles for eight mares challenged with the 
virulent, recombinant Bucyrus strain of EAV 
 
Figure 3.3 Square root-transformed lymphocyte response profiles 
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The population parameters characterize the mean lymphocyte response of mares 
to inoculation with the Bucyrus strain of EAV. (More accurately, they represent the mean 
infection response parameter values for the populations from which the sample was 
drawn. If the samples were selected at random from a well-defined population then the 
posterior means can be interpreted as estimates of the true mean values within the source 
population.) On the transformed (square root) scale, the mean population baseline 
lymphocyte level was estimated to be 1.6 𝐾/𝜇𝐿, with a posterior 95% credible interval 
(1.5, 1.7). Thus, the probability is 95% that the true (transformed) population baseline 
lymphocyte level is between 1.5 and 1.7 𝐾/𝜇𝐿 . The mean population time to peak 
response was 8.3 days (7.6, 9.0), and the maximum decline in lymphocyte level was -0.8 
𝐾/𝜇𝐿 (-1.0, -0.6). The mean population 𝐹𝑊𝐻𝑀 was 5.5 days (4.4, 6.8), and the large 
difference in 𝐻𝑊𝐻𝑀𝑙  [4.1 (3.1, 5.1)] and 𝐻𝑊𝐻𝑀𝑟 [1.4 (1.2, 2.2)] indicates that the time 
from onset to maximum lymphocyte decrease was nearly triple the time for the return 
from peak to baseline lymphocyte level.  
The variance component estimates quantify the extent to which individual 
lymphocyte response parameters may vary about their corresponding population mean 
values. Thus for example, for a particular mare from the source population inoculated 
with the Bucyrus strain of EAV, it would be unusual to observe a maximum drop in 
(square root-transformed) lymphocyte count of less than 𝐼 − 1.96𝜎𝐼 = −0.4 𝐾/𝜇𝐿 below 
baseline count or more than  𝐼 + 1.96𝜎𝐼 = −1.2 𝐾/𝜇𝐿 below baseline. The population 
mean response curve is presented in Figure 3.4.  
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Table 3.1. Posterior estimates of population lymphocyte response parameters following 
challenge of eight mares with the virulent, recombinant Bucyrus strain of EAV 
Parameter Mean 2.5% quantile 97.5% quantile 
Population infection response parameters 
𝐵 1.6 1.5 1.7 
𝐼 -0.8 -1.0 -0.6 
𝑝 8.3 7.6 9.0 
𝐹𝑊𝐻𝑀 5.5 4.4 6.8 
𝐻𝑊𝐻𝑀𝑙  4.1 3.1 5.1 
𝐻𝑊𝐻𝑀𝑟  1.4 1.2 2.2 
Variance components 
𝜎𝐵 0.22 0.12 0.42 
𝜎𝐼 0.21 0.05 0.47 
𝜎𝑝 0.32 0.01 0.96 
𝜎𝑙𝑜𝑔 𝑙 0.17 0.01 0.50 
𝜎𝑙𝑜𝑔 𝑟 0.92 0.09 1.94 
𝜎 0.68 0.03 1.85 
 
 
 
Figure 3.4. Population lymphocyte response curve, with pointwise 95% posterior 
credible intervals, for eight mares following experimental challenge with the virulent, 
recombinant Bucyrus strain of EAV. Circles indicate observed lymphocyte counts. 
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3.3.2. Febrile response to equine arteritis virus infection in horses 
For our second example we revisit the comparison of population febrile responses 
to the Bucyrus and Kentucky-84 strains of EAV. This example was discussed in Chapter 
2 where we modeled the febrile responses using the symmetric normal-errors NLHM 
(2.1)-(2.7). To review briefly, two separate experiments were conducted in which core 
body temperature (CBT) was observed on days -7, -4 and -2 prior to inoculation and on 
days 0, 2, 4, 6, 8, 10, 12 and 14 post-inoculation (DPI). In one of the experiments eight 
mares were challenged with the Bucyrus strain of EAV whereas in the second eight 
stallions were challenged with the KY-84 strain. Figure 3.5 presents the observed, 
subject-specific febrile response profiles for the two groups.  
Figure 3.5 Observed febrile response profiles for eight mares challenged with the 
Bucyrus strain of EAV, and eight stallions challenged with the Kentucky-84 strain 
All sixteen profiles suggest a single-peaked response with a common pre- and 
post-infection baseline body temperature. We modeled the febrile responses using the 
asymmetric normal-errors NLHM in (3.3)-(3.6), with 𝑔 ∈ {1,2}.  Satisfactory 
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convergence was achieved with 100,000 MCMC iterations per three chains, including 
25,000 burn-in. Convergence diagnostics and supplemental plots are included in 
Appendix A. Posterior estimates are summarized in Table 3.2. 
In many respects the febrile responses of the two groups were quite similar. The 
estimates of baseline CBT for example, 𝐵(1) = 99.4℉ and 𝐵(2) = 99.3℉, are nearly 
identical as might be expected. However they differed with respect to peak fever intensity 
and time to peak fever. On average, in the stallions challenged with the KY-84 strain, the 
febrile response peaked 𝑝(2) = 7.1 days after inoculation at an intensity of 𝐼(2) = 4.7℉ 
above baseline CBT. The 95% posterior credible intervals (CI) for 𝑝(2) and 𝐼(2) indicate 
that the true population means for time-to-peak and peak intensity could plausibly lie in 
the intervals (6.6, 7.4) and (4.1, 5.2), respectively. By comparison, in the mares 
challenged with the Bucyrus strain, the febrile response peaked 𝑝(1) = 7.8 days (7.3, 8.4) 
after inoculation at an intensity of 𝐼(1) = 3.5℉ (2.7, 4.2) above baseline CBT.  
Expressing the posterior means for the scale parameters 𝑙(𝑔) and 𝑟(𝑔)in terms of 
𝐻𝑊𝐻𝑀 and 𝐹𝑊𝐻𝑀 increases their interpretability, so we report only those means in 
Table 3.2.  We see that there was little difference between the groups in the mean 
duration of the febrile response, with 𝐹𝑊𝐻𝑀(1) = 5.7 days (4.8, 7.2) and 𝐹𝑊𝐻𝑀(2) =
5.6 days (4.8, 6.5). The response in both groups was strongly asymmetric as indicated by 
the posterior means for 𝐻𝑊𝐻𝑀𝑙
(1)
 and 𝐻𝑊𝐻𝑀𝑙
(2)
 being more than three times the 
posterior means for 𝐻𝑊𝐻𝑀𝑟
(1)
 and 𝐻𝑊𝐻𝑀𝑟
(2)
. In other words, recovery from fever was 
much more abrupt than onset. 
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Table 3.2. Posterior estimates of population febrile response parameters following 
challenge of eight mares with the Bucyrus strain of EAV and eight stallions with the KY-
84 strain of EAV 
Bucyrus strain (mares) KY-84 strain (stallions) 
 
Parameter 
 
Mean 
2.5% 
quantile 
97.5% 
quantile 
 
Parameter 
 
Mean 
2.5% 
quantile 
97.5% 
quantile 
Population infection response parameters 
𝐵(1) 99.4 99.0 99.8 𝐵(2) 99.3 98.9 99.6 
𝐼(1) 3.5 2.7 4.2 𝐼(2) 4.7 4.1 5.2 
𝑝(1) 7.8 7.3 8.4 𝑝(2) 7.1 6.6 7.4 
𝐹𝑊𝐻𝑀(1) 5.7 4.8 7.2 𝐹𝑊𝐻𝑀(2) 5.6 4.8 6.5 
𝐻𝑊𝐻𝑀𝑙
(1)
 4.3 3.5 5.1 𝐻𝑊𝐻𝑀𝑙
(2)
 4.3 3.5 5.1 
𝐻𝑊𝐻𝑀𝑟
(1)
 1.4 1.2 2.5 𝐻𝑊𝐻𝑀𝑟
(2)
 1.3 1.2 1.7 
Variance components 
𝜎𝐵
(1)
 0.46 0.17 0.97 𝜎𝐵
(2)
 0.44 0.15 0.94 
𝜎𝐼
(1)
 0.90 0.34 1.91 𝜎𝐼
(2)
 0.55 0.06 1.33 
𝜎𝑝
(1)
 0.23 0.01 0.74 𝜎𝑝
(2)
 0.27 0.01 0.74 
𝜎𝑙𝑜𝑔 𝑙
(1)
 0.09 0.00 0.30 𝜎𝑙𝑜𝑔 𝑙
(2)
 0.18 0.03 0.43 
𝜎𝑙𝑜𝑔 𝑟
(1)
 0.81 0.04 3.07 𝜎𝑙𝑜𝑔 𝑟
(2)
 0.23 0.01 0.70 
𝜎 0.68 0.62 0.75 𝜎 0.68 0.62 0.75 
 
Interpretation of the variance component estimates is the same as in the one-
sample case. Thus for example, for a particular mare from the source population 
inoculated with the Bucyrus strain of EAV, it would be quite unusual to observe a fever 
that peaked at less than 𝐼(1) − 1.96𝜎𝐼
(1)
= 1.7℉ above baseline CBT or at higher than  
𝐼(1) + 1.96𝜎𝐼
(1)
= 5.3℉  above baseline. The population response curves for the two 
groups are presented in Figure 3.6.  
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Figure 3.6. Population febrile response curves, with pointwise 95% posterior credible 
intervals, for mares challenged with the Bucyrus strain of EAV, and stallions challenged 
with the Kentucky-84 strain 
 We can contrast the population response parameters for the two groups simply by 
monitoring the posterior distributions of their differences. These are presented in Table 
3.3 for baseline, peak fever intensity, time to peak fever, and response duration as 
indexed by 𝐹𝑊𝐻𝑀.  We see that zero is excluded from the posterior 95% CI’s for the 
differences in both peak intensity and time to peak. We conclude that the febrile 
responses of the two groups differ with respect to these two characteristics. 
Table 3.3. Posterior estimates of group differences in population parameters 
 
Parameter 
 
Mean 
Standard 
deviation  
2.5% 
quantile 
97.5% 
quantile 
𝐵(2)−𝐵(1) -0.11 0.28 -0.66 0.44 
𝐼(2)−𝐼(1) 1.2 0.48 0.25 2.2 
𝑝(2)−𝑝(1) -0.72 0.34 -1.4 -0.1 
𝐹𝑊𝐻𝑀(2) − 𝐹𝑊𝐻𝑀(1) -0.14 0.83 -1.8 1.1 
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In comparing the asymmetric analysis in this section with the symmetric analysis 
in Chapter 2 we note that the asymmetric model placed the time to peak estimates for 
both groups about 1.5 days earlier than did the symmetric model.  
3.4. ESTIMATION AND INFERENCE FOR ONSET AND RECOVERY TIMES 
IN THE NORMAL-ERRORS NLHM 
The normal-errors NLHM developed in Chapters 2 and 3 was specified in such a 
way that its parameters would correspond to biologically meaningful properties of the 
infection response. In the asymmetric model (3.3)-(3.6), the baseline response level is 
represented by 𝐵, the peak response intensity by 𝐼, and the time to peak response by p.  
The parameters 𝑟 and 𝑙 can be viewed as indices of, respectively, the duration of the onset 
and recovery phases of the response. Although adequate for testing hypotheses about 
differences in the duration of onset or recovery, or the total response duration, among 
treatment groups, these scale parameters lack satisfying descriptive interpretations. 
Quantities derivable from 𝑟 and 𝑙, such as HWHM and FWHM, can partially address the 
need for more intuitive measures of response duration. However for investigators 
interested in questions such as, “On average, how many days (or hours) after inoculation 
does the response onset (or recovery) occur?” or “Does treatment alter the timing of 
response onset (or recovery)?” none of these measures is adequate. In this section we 
propose a method of estimating the timing of response onset and recovery for the normal-
errors NLHM. 
3.4.1. Method 
The model (3.3)-(3.6) is appropriate for response variables which vary in a 
consistent manner about some mean level prior to challenge, during infection, and 
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following recovery. This follows from the distributional assumption about the response 
variable specified in (3.3). Observe that for an individual in its baseline, uninfected state, 
the response distribution specified in (3.3) and (3.4) simplifies to 
𝑦𝑖𝑗|𝐵𝑖~𝑁(𝐵𝑖, 𝜎
2)        (3.9) 
Thus, in the baseline state 95% of an individual’s observed responses will fall 
within the interval [𝐵𝑖 − 1.96𝜎, 𝐵𝑖 + 1.96𝜎]. Intuitively, a series of observations falling 
outside that interval in the same direction (either all above or all below) would be a 
strong indication that onset had occurred for that particular individual.  
Now consider selecting an uninfected individual at random from the source 
population and sampling the response variable. Without knowing that particular 
individual’s true baseline level, a reasonable expectation for the observed value would be 
the population baseline 𝐵. But the specific value we observe is influenced both by the 
inherent variability in the individual’s responses and the amount by which the 
individual’s baseline differs from the population baseline 𝐵. In the model these quantities 
are represented by 𝜎2 and 𝜎𝐵
2. Thus, marginally over the entire population, we have 
𝑦𝑖𝑗~𝑁(𝐵, 𝜎𝐵
2 + 𝜎2)        (3.10) 
It follows that approximately 95% of all observations made under baseline (i.e. 
uninfected) conditions will fall within the interval  
[𝐵 − 1.96√𝜎2 + 𝜎𝐵
2, 𝐵 + 1.96√𝜎2 + 𝜎𝐵
2].       (3.11) 
We can think of this interval as representing bounds on normal variability of the 
response variable among uninfected individuals in the sources population. When model 
(3.3)-(3.6) is fitted to data from an EI study we obtain an estimate of the population 
average response to infection. We define population average onset time as the earliest 
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time point at which the population average response (𝑂) departs from this interval of 
normal variability. Similarly, we define the population average recovery time (𝑅) as the 
earliest time at which the population average response returns to the interval of normal 
variability. Finally, we define population average response duration as the time between 
onset and recovery, i.e. 𝐷 = 𝑅 − 𝑂.  
3.4.2. Procedure 
In the Bayesian setting implementation is trivial. After the final model is fit, 
posterior distributions for 𝑂 , 𝑅  and 𝐷  can be obtained as follows. For each MCMC 
iteration: 
1. Reconstruct the population mean response curve from the parameter 𝜷(𝑚) 
obtained for that iteration.  [Note that the (𝑚) superscript in this context refers to 
the sampled value obtained at MCMC iteration 𝑚, and is not to be confused with 
the  (𝑔) superscript notation used in (3.5) and (3.6) to denote group membership.] 
2. Extract the parameter values B(𝑚), σ(𝑚) and 𝜎𝐵
(𝑚)
 obtained at that iteration.  
3. Determine the earliest time at which the population mean response curve for 
iteration 𝑚 escapes the interval (3.11). This is the estimated population average 
onset time for iteration 𝑚, denoted O(𝑚); 
4. Determine the earliest time at which the population mean response curve for 
iteration 𝑚 returns to the interval (3.11). This is the estimated population average 
recovery time for iteration 𝑚, denoted R(𝑚); 
5. Define the estimated population average response duration for iteration 𝑚  as 
D(𝑚) = R(𝑚) − O(𝑚). 
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Collect the MCMC estimates O(𝑚),  R(𝑚)  and 𝐷(𝑚)  into vectors 𝑶 , 𝑹  and 𝑫 . 
These vectors represent samples from the posterior distributions of 𝑂 , 𝑅  and 𝐷  from 
which posterior means and credible intervals may be extracted.  
3.4.3. Illustrative example: Lymphocyte count 
Figure 3.7 presents population mean onset and recovery times of the lymphocyte 
response for mares challenged with the recombinant Bucyrus strain of EAV. The vertical 
blue line at 4.7 DPI on the x-axis indicates that the decline in lymphocyte count was first 
detectable, on average, at 4.7 days post-challenge. The lighter blue rectangular region 
surrounding this line indicates the posterior 95% credible interval (3.3, 6.9). Similarly, 
the vertical blue line at 9.4 DPI on the x-axis indicates that return to baseline lymphocyte 
count occurred, on average, 9.4 days post-challenge. The light blue region surrounding 
this line indicates the posterior 95% credible interval for recovery (8.5, 10.7). The total 
duration of the lymphocyte response – the time from initial onset to recovery to baseline 
level – was estimated to be 4.7 days (1.8, 6.8).  
  
Figure 3.7.  Estimated population mean onset and recovery times for lymphocyte 
response for mares challenged with the recombinant Bucyrus strain of EAV 
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3.4.4. Illustrative example: Febrile response  
Figure 3.8 presents population mean onset and recovery times of the febrile 
response to EAV infection for mares challenged with the recombinant Bucyrus strain of 
EAV and stallions challenged with the KY-84 strain. The vertical blue line at 3.4 DPI on 
the x-axis indicates that in the Bucyrus group the onset of fever occurred at 3.4 days post-
challenge. The lighter blue rectangular region surrounding this line indicates the posterior 
95% credible interval (2.2, 4.9). Similarly, the vertical blue line at 9.1 DPI on the x-axis 
indicates that return to baseline body temperature in the Bucyrus group occurred, on 
average, 9.1 days post-challenge. The light blue region surrounding this line indicates the 
posterior 95% credible interval for recovery (8.5, 10.6).  
 
Figure 3.8.  Estimated population mean onset and recovery times for febrile response to 
EAV infection. Bucyrus strain (mares) 
Onset and recovery estimates and accompanying credible intervals for the KY-84 
group are indicated by the orange lines and rectangular regions. Estimated onset for that 
group was considerably earlier at 1.8 days (0.6, 3.1) and recovery was also slightly earlier 
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at 8.7 days (8.2, 9.2). However as suggested by the overlapping credible intervals 
(illustrated by the brownish regions in Figure 3.8), neither of these differences was 
judged to be statistically significant. The estimated group difference in duration of the 
febrile response [Bucyrus 5.8 days (3.7, 7.7) and KY-84 6.8 (5.3, 8.2)] was likewise not 
significant. Note that the mean duration estimate for the KY-84 group is 21% higher than 
the estimate of mean FWHM from Table 3.2, but the estimate for the Bucyrus group is 
less than 2% greater.    
3.5.  DISCUSSION 
Our primary aim in this chapter was to extend the normal-errors NLHM model to 
accommodate asymmetric responses. To accomplish this we proposed a mean response 
function consisting of two half-Gaussian curves constrained to meet at a common peak. 
There are several other examples in that statistical literature of piecewise models for 
peaked, asymmetric longitudinal responses. Huisman et al (1993) proposed a set of five 
response functions for modeling temporal variations in the abundance of vegetation 
species in response to environmental changes. The models are based on logistic equations 
of the form (1 + 𝑒𝑎+𝑏𝑥)−1 . Two of the curves are analogous to our symmetric and 
asymmetric Gaussian-based response models. Müller and Rosner (1997) introduced a 
model for analyzing the hematologic (white blood cell) response of patients to 
chemotherapeutic medications. They used a piecewise linear and logistic response 
function consisting of a linear baseline component, a logistic “recovery” component, and 
a second linear “onset” component connecting the baseline and recovery portions of the 
curve. Gössl et al (2001) proposed a model for the hemodynamic response function 
(HRF) which arises in functional magnetic resonance imaging (fMRI). Neuronal 
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activation in the brain in response to an experimental stimulus results in local increases in 
blood flow and oxygen level. These changes follow a well-defined pattern known as the 
hemodynamic response. The HRF of G ö ssl and colleagues is a piecewise function 
consisting of two linear and three truncated Gaussian components for a total of five 
regions (baseline, increase, plateau, decrease and undershoot).  
We implemented our infection response model as a Bayesian hierarchical 
nonlinear model. The primary reason for this decision was the inability of frequentist 
methods to achieve convergence when using the piecewise response function (3.4). Jang 
et al (2013) reported successfully fitting several piecewise mixed effects models of 
cardiac function using frequentist methods, specifically the nlme package in R. However 
their data set included 80 observations per individual. This suggests that our difficulties 
may have been due to the relatively sparsity of our data at the individual level. A second 
reason for preferring the Bayesian approach is that maximum likelihood estimation and 
inference for NHLM’s are based on asymptotic results that may not hold for the relatively 
small numbers of subjects typical of EI studies. The hematologic and hemodynamic 
response models mentioned above were both implemented as Bayesian hierarchical 
nonlinear models. 
3.5.1. Illustrative examples 
 
The illustrative examples highlight some concerns that can only be addressed by the 
investigator at the time of study design. Intensity of measurement occasions at the 
individual level appears to be a critical factor in the feasibility of applying piecewise 
NLHM’s to longitudinal EI data. Based on both the illustrative examples and the 
simulation results from Chapter 2, we can make some recommendations. In general, we 
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advise sampling as intensively as practically possible over the duration of the response. 
However there are certain periods during which sampling intensity is particularly 
relevant. First, we advise taking several baseline measurements both pre-challenge and 
post-recovery in order to better locate the individual baseline response levels. Second, we 
advise sampling intensively during periods when the response variable is expected to 
change rapidly, which for a single-peaked response means during the onset and recovery 
phases. In the febrile response example, core body temperature for all horses dropped 
rapidly after peaking. In many cases rapid onset will occur within the first two or three 
days post-inoculation, particularly with quantities like viral load as we will discuss in 
Chapter 4, so intensively sampling is advisable during this period. 
The febrile response example illustrates yet another attractive feature of a 
Bayesian implementation. Recall that in Chapter 2 the symmetric NLHM was 
implemented as a frequentist nonlinear mixed effects model. It is well known that 
variance components tend to be underestimated by maximum likelihood (ML) methods 
for both linear and nonlinear mixed models, because they do not take into account the 
loss in degrees of freedom incurred in estimating the fixed effects.  To enable a 
comparison of variance component estimates for the ML and Bayesian approaches, we 
reanalyzed the febrile response data from Section 3.3.2 using the symmetric NLHM from 
Chapter 2, but implemented as a Bayesian NLHM. We found that the posterior means for 
𝜎𝐵 , 𝜎𝐼 and 𝜎𝑝 were between 12% and 26% higher than the ML estimates from Chapter 2. 
Restricted maximum likelihood (REML) estimation often produces more accurate 
variance component estimates than ML (Harville 1977). However in this particular 
example, the REML and ML estimates were nearly identical. 
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3.5.2. Estimation and inference for response onset and recovery 
 
 There are some examples in the literature of methods used to identify onset and 
recovery times in longitudinal responses. Fox (2008) used RM-ANOVA to estimate the 
time at which postural control (essentially, balance) returned to baseline level after 
exercise. They found that “the effects of fatigue persisted for up to 13 minutes before 
postural control returned to baseline.” As a result it was recommended that clinicians 
responsible for assessing athletes for concussions during play or practice should wait at 
least 13 minutes so that effects due to fatigue are not mistakenly interpreted as a sign of 
concussion.  
Piecewise models such as those discussed above contain built-in change point 
parameters that can be used to estimate the timing of key transitions in the response 
trajectory. For example the hematologic response model by M?̈?ller and Rosner includes a 
parameter that marks the transition point from the baseline phase, modeled as a horizontal 
line, to the onset phase, which is modeled as a separate line connecting the baseline 
segment to the recovery segment.  
Our approach aims to identify the population average time at which a clinically 
meaningful change in the response variable from the baseline, uninfected state is 
detectable. This is different from the time at which the underlying immune response to 
infection commences. We note also that in the frequentist setting, it would be possible to 
apply the same approach to estimating population mean onset, recovery and duration via 
the bootstrap (Efron 1979,  Das 1999). 
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CHAPTER FOUR 
A Bayesian nonlinear hierarchical model for viral load 
4.1.  INTRODUCTION 
In Chapter 3, we presented a Bayesian normal-errors NLHM for asymmetric 
infection responses. Frequently in MC experiments involving viral pathogens, a primary 
focus is the time course of the viral load in blood, feces or other fluids or excreta. For the 
individuals in such experiments, viral load will be exactly zero at all observation times 
prior to inoculation and after clearance of the virus. During infection, however, viral load 
can be viewed as fluctuating randomly about some systematic trajectory (Figure 4.1).  
Because viral loads are nonnegative, the assumption of identical, normally 
distributed errors is clearly untenable. We propose an NLHM in which the viral load at 
each time point is modeled as a Poisson random variable with mean given by a compact 
kernel function such as the Tricube or Epanechnikov. Because the variance of a Poisson 
random variable is equal to its mean, when the mean viral load is equal to zero (i.e. pre-
onset or post-recovery) the variance will be also. Similarly, when the mean viral load is 
positive (i.e. during infection) the variance will be positive, and the variance will increase 
with the mean.  
 In this Chapter we propose a NLHM suitable for modeling viral load and other 
response variables that do not vary when the subject is not infected. We provide two 
illustrative examples in which the proposed model is applied to viral load data from 
actual experimental infection studies.  
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Figure 4.1.  A typical nasal viral load response profile for a human subject 
experimentally infected with rhinovirus (Mallia 2012)  
4.2. BAYESIAN NONLINEAR HIERARCHICAL MODEL FOR VIRAL LOAD 
We model the individual response profiles with piecewise half-kernel functions, 
where K in (16) is any nonnegative, compact kernel function. The normalizing constant is 
replaced with an intensity parameter 𝐼𝑖 which is specific to each individual and 
corresponds to mean peak intensity. Because viral load has a natural baseline value of 
zero, subject-specific baseline parameters, as in (8), are not required. 
Level 1 (model of intra-individual variability) 
𝑦𝑖𝑡~𝑃𝑜𝑖𝑠(𝜇𝑖𝑡)        (4.1) 
𝜇𝑖𝑡 = 𝐾
∗(𝑡, 𝑝𝑖 , 𝑙𝑖, 𝑟𝑖)        (4.2) 
𝐾∗(𝑡) =
{
 
 
 
 
 
 0  if  𝑡 ≤ 𝑝𝑖 − 𝑙𝑖
𝐼𝑖 × 𝐾 (
𝑡−𝑝𝑖
𝑙𝑖
) if  𝑝𝑖 − 𝑙𝑖 < 𝑡 ≤ 𝑝𝑖
𝐼𝑖 × 𝐾 (
𝑡−𝑝𝑖
𝑟𝑖
) if  𝑝𝑖 < 𝑡 < 𝑝𝑖 + 𝑟𝑖
0 if  𝑡 ≥ 𝑝𝑖 + 𝑟𝑖
     (4.3) 
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An attractive consequence of using a compact kernel 𝐾 in the specification of the 
mean infection response function 𝐾∗ is that we obtain estimates of response onset time 
for individual i as 𝑝𝑖 − 𝑙𝑖, recovery time as 𝑝𝑖 + 𝑟𝑖, and response duration as 𝑑𝑖 = 𝑝𝑖 +
𝑟𝑖 − (𝑝𝑖 − 𝑙𝑖) = 𝑙𝑖 + 𝑟𝑖. 
Level 2 (model of inter-individual variability) 
Collect the response parameters for individual 𝑖, into a vector 
𝜷𝑖 = [𝐼𝑖, 𝑝𝑖 , 𝑙𝑖 , 𝑟𝑖]
𝑇 .         (4.4) 
Level 2 (model of inter-individual variability) 
𝜷𝑖 = 𝜷
(𝑔) + 𝒃𝑖         (4.5) 
𝒃𝑖~𝑁(0,𝑫
(𝑔)), where 𝑫(𝑔) = diag (𝜎
𝐼(𝑔)
2 , 𝜎
𝑝(𝑔)
2 , 𝜎
𝑙(𝑔)
2 , 𝜎
𝑟(𝑔)
2 )   (4.6) 
Level 3 (hyperprior distribution) 
 Prior distributions on 𝜷, 𝑫, and 𝜎 were the same as for the normal-errors model in 
Chapter, with one exception. Because the response onset cannot occur prior time zero, we 
have 𝑝 − 𝑙 ≥ 0 ⇒ 𝑙 < 𝑝. Thus we can specify 𝑙~𝑈𝑛𝑖𝑓(0, 𝑝). 
As previously, the following definitions are implicit in (4.1)-(4.6). 
𝜷𝑖 = [𝐼𝑖, 𝑝𝑖 , 𝑙𝑖 , 𝑟𝑖]
𝑇 .         (4.7) 
𝜷(𝑔) = [𝐼(𝑔), 𝑝(𝑔), 𝑙(𝑔), 𝑟(𝑔)]
𝑇
, 𝑔 ∈ {1,2}       (4.8) 
4.3.  ILLUSTRATIVE EXAMPLES 
4.3.1.  Effect of body condition on viral shedding in migratory birds 
This example refers to the case study from Chapter 1 on influenza A viral 
shedding in ducks. Recall that the original experiment included four treatment groups. 
For the sake of simplicity we focus here on a comparison of the viral shedding pattern of 
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the wild lean group to that of the wild normal group. Viral shedding profiles are 
presented in Figure 4.2. Peak shedding for birds in the wild normal group generally was 
higher than in wild lean birds, although there were exceptions. Mean duration of 
shedding also appears to be longer in the wild normal group.  
Figure 4.2. Observed viral shedding profiles for nine wild-caught ducks with normal 
body condition and nine wild-caught ducks with lean body condition following 
experimental challenge with AIV (observations for days 11 through 28 not shown) 
We modeled the viral shedding data using the Poisson NLHM in (4.1)-(4.6) with 
𝑔 ∈ {1,2}. Based on the observed profiles in Figure 4.2 we selected a piecewise Tricube 
kernel function as the model for the mean response functions. Thus the function 𝐾 in 
(4.3) is given by  
𝐾(𝑢) =  (1 − |𝑢|3)3.        (4.9) 
Satisfactory convergence was achieved with 175,000 MCMC iterations following 
25,000 burn-in, for all except the recovery parameters in the wild lean group, i.e. 𝑟(2) and 
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𝜎𝑟
(2)
. We discuss possible causes in §4.5. Convergence diagnostics and supplemental 
plots are included in Appendix A. Posterior estimates are reported in Table 4.1. 
Table 4.1. Posterior estimates of population viral shedding parameters for wild normal 
and wild lean groups experimentally challenged with AIV 
Wild-caught normal Wild-caught lean 
 
Parameter 
 
Mean 
2.5% 
quantile 
97.5% 
quantile 
 
Parameter 
 
Mean 
2.5% 
quantile 
97.5% 
quantile 
Population infection response parameters 
𝐼(1) 470 355 584 𝐼(2) 331 197 468 
𝑝(1) 1.9 1.3 2.5 𝑝(2) 2.5 1.4 3.7 
𝑙(1) 1.3 0.4 2.0 𝑙(2) 1.5 0.2 2.8 
𝑟(1) 4.4 3.4 5.0 𝑟(2) 3.4 1.3 4.9 
Variance components 
𝜎𝐼
(1)
 166 98 291 𝜎𝐼
(2)
 189 110 341 
𝜎𝑝
(1)
 0.93 0.55 1.6 𝜎𝑝
(2)
 1.8 1.0 3.2 
𝜎𝑙
(1)
 1.3 0.8 1.9 𝜎𝑙
(2)
 2.7 1.6 4.5 
𝜎𝑟
(1)
 1.9 1.7 2.0 𝜎𝑟
(2)
 3.1 1.8 4.8 
 
Figure 4.3 illustrates the population average time courses for influenza viral 
shedding in the wild normal and wild lean groups. The estimated time to peak was earlier 
in the wild normal group (1.9 days to 2.5 days) and the mean peak shedding intensity was 
139 units [𝑙𝑜𝑔10(𝐺𝐸𝐶)/140 𝜇𝑙] greater. 
Table 4.2 summarizes the posterior distributions for the group differences in the 
population infection response parameters. The posterior interval (-314, 38) for  
𝐼(2) − 𝐼(1)  includes zero, implying that peak viral shedding intensity was significantly 
greater in the captive normal group. The interval for 𝑝(2) − 𝑝(1) includes zero, implying 
no difference in mean time to peak shedding.  
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Table 4.2. Posterior estimates of differences in population viral shedding 
parameters for wild normal and wild lean groups challenged with AIV 
 
Parameter 
 
Mean 
95% posterior credible interval 
2.5% quantile 97.5% quantile 
𝐼(2) − 𝐼(1) -139 -314 38 
𝑝(2) − 𝑝(1) 0.6 -0.7 1.9 
(1)
 denotes normal body condition and 
(2)
 denotes lean body condition 
 
 
Figure 4.3.  Estimated population viral shedding curves, with pointwise 95% posterior 
credible intervals, for wild normal and wild lean groups challenged with AIV 
4.3.2. Effects of rhinovirus infection in chronic obstructive pulmonary disease 
 Our second example refers to the case study from Chapter 1 on the effect of 
rhinovirus infection on persons with chronic obstructive pulmonary disease (COPD). To 
review briefly, Mallia and colleagues (2006, 2011, 2012, 2013) recently developed a 
human rhinovirus (HRV) challenge model for COPD. In their 2011 study, thirteen 
volunteers with COPD and thirteen controls with a similar smoking history, but normal 
lung function, were recruited. All participants tested negative for serum neutralizing 
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antibodies to rhinovirus 16 (RV-16). They were inoculated with a 10 TCID50 dose of RV-
16 and followed for six weeks post-infection. Viral loads in nasal lavage and sputum, 
lung function, inflammatory markers, and upper and lower respiratory symptom scores 
were sampled at varying intervals and intensities. Twenty-three subjects displayed 
virological evidence of rhinovirus infection: eleven from the COPD group and twelve 
from the control group. Data from those 23 subjects were analyzed to assess whether 
experimental RV-16 infection induces exacerbation in persons with COPD.  
Figure 4.4. Observed profiles of viral load in nasal lavage for eleven subjects with COPD 
and twelve health controls following experimental challenge with RV-16 
 Our interest in this example is in the viral load in nasal lavage (VLN). Figure 4.4 
presents the observed viral loads in nasal lavage (VLN) following inoculation over the 
course of six weeks, for all subjects in each group. In each group the viral load increases 
to a peak very rapidly for most subjects and decreases back to zero more gradually, as the 
host immune response neutralizes and eliminates the virus.  The figure suggests that the 
mean time to complete viral clearance may be greater in the control group, although this 
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impression is based largely on just two control subjects with clearance times greater than 
thirty days. 
As in the previous example we modeled the rhinovirus data using the Poisson 
model in (4.1)-(4.6) with 𝑔 ∈ {1,2} . Again we selected a piecewise Tricube kernel 
function (4.9) as the model for the mean response functions, although other kernel 
functions could be used. Satisfactory convergence of the Markov chains was achieved 
with 200,000 MCMC iterations (50,000 burn-in) for all except for the onset parameters in 
both groups, i.e. 𝑙(1),  𝑙(2),  𝜎𝑙
(1)
 and 𝜎𝑙
(2)
. We discuss the cause of these exceptions in 
§4.5. Convergence diagnostics and supplemental plots are included in Appendix A.   
Table 4.3. Posterior estimates of population viral load response parameters for controls 
and subjects with COPD 
Controls COPD 
 
Parameter 
 
Mean 
2.5% 
quantile 
97.5% 
quantile 
 
Parameter 
 
Mean 
2.5% 
quantile 
97.5% 
quantile 
Population infection response parameters 
𝐼(1) 550 456 644 𝐼(2) 610 442 778 
𝑝(1) 3.3 1.6 4.9 𝑝(2) 2.8 0.83 5.0 
𝑙(1) 0.75 0.06 1.5 𝑙(2) 1.3 0.15 2.6 
𝑟(1) 17.4 14.6 20.2 𝑟(2) 15.8 12.8 18.8 
Variance components 
𝜎𝐼
(1)
 148 92 248 𝜎𝐼
(2)
 248 151 416 
𝜎𝑝
(1)
 2.7 1.7 4.3 𝜎𝑝
(2)
 4.0 1.9 8.1 
𝜎𝑙
(1)
 1.2 0.5 2.2 𝜎𝑙
(2)
 2.2 1.4 3.7 
𝜎𝑟
(1)
 4.95 4.82 5.0 𝜎𝑟
(2)
 4.8 4.5 5.0 
 
Posterior estimates are reported in Table 4.3. Figure 4.5 illustrates the population-
averaged time courses for RV-16 viral load in nasal lavage in the COPD and control 
groups. Peak viral load was reached earlier in COPD subjects, at 2.8 days (0.8, 5.0) 
compared to 3.3 days (1.6, 4.9) in controls. Peak intensity was estimated at 610 units 
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(442, 778) in the COPD group compared to 550 units (456, 644) in controls. Thus, the 
average response in the COPD group began earlier and peaked earlier at a higher level 
than the average response in the control group.   
 
Figure 4.5. Estimated population time course for viral load in nasal lavage, following 
RV-16 challenge with pointwise 95% posterior credible intervals 
 Table 4.4 summarizes the posterior distributions for the group differences in peak 
intensity and time to peak. We see that both posterior 95% credible intervals include the 
null value of zero, suggesting that the differences described above are indistinguishable 
from random noise. Thus, although the original analysis detected a difference in viral 
loads between COPD subjects and controls at 6 DPI, our analysis found no significant 
difference in the population average response curves. This is noteworthy because it is 
unclear why one would expect COPD to influence the time course of viral load, and a 
false positive finding can be a distraction.  
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Table 4.4. Posterior estimates of differences in population viral load 
response parameters for controls and subjects with COPD 
 
Parameter 
 
Mean 
95% posterior credible interval 
2.5% quantile 97.5% quantile 
𝐼(2) − 𝐼(1) 60.0 -130.9 251.4 
𝑝(2) − 𝑝(1) -0.5 -3.0 2.2 
(1)
 denotes the control group and 
(2)
 denotes the COPD group 
 
4.4. ONSET AND RECOVERY TIMES IN THE VIRAL LOAD NLHM 
In Chapter 3, we introduced a method for estimating onset and recovery times for 
the normal-errors NHLM. The approach was based on identifying limits on the plausible 
values for the mean response when all the individuals in a sample are in the baseline, or 
nonresponsive, state. For the viral load NHLM (4.1)-(4.6) the solution to this problem is 
trivial: natural candidates for onset and recovery time can be obtained as direct functions 
of the model parameters. A glance at equation (4.3) shows that the transition from zero to 
positive viral load occurs at time 𝑝𝑖 − 𝑙𝑖, and the return from positive to zero viral load 
occurs at time 𝑝𝑖 + 𝑟𝑖. We define these times, respectively, as the population mean onset 
and recovery times, and we estimate them with posterior means and credible intervals. 
Figure 4.6 presents population mean onset and recovery times for the captive 
normal group from the viral shedding example in §4.3.1. The vertical blue line at 0.59 
DPI on the x-axis indicates that in the wild normal treatment group the onset of fever 
occurred at 0.59 days (or about 14 hours) post-challenge. The light blue shaded region 
surrounding this line indicates the posterior 95% credible interval (0.03 1.5). Similarly, 
the vertical blue line at 6.3 DPI on the x-axis indicates that viral shedding in the captive 
normal group ceased, on average, 6.3 days post-challenge. The posterior 95% credible 
interval for recovery is (5.1, 7.1).  
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Figure 4.6. Estimated onset and recovery times, with posterior 95% credible intervals, 
for wild normal ducks challenged with AIV 
Figure 4.7 illustrates onset and recovery for the wild-caught, lean treatment group. 
Estimated onset for the wild lean group was later at 0.96 days (0.04, 2.64), or about 23 
hours, and the point estimate for recovery was slightly earlier at 5.9 days (3.4. 7.9). 
However the posterior credible intervals indicate that there is a great deal of uncertainty 
in these point estimates. Figures A.17 and A.18 are panel plots of the individual, 
observed viral shedding profiles. In both groups, there are very few observations within 
the time intervals where onset and recovery occur, but the problem is particularly evident 
in the wild lean group (Figure A.18). This likely explains the extreme lack of precision in 
the onset and recovery estimates for that group. As a result, although the point estimates 
of recovery time and response duration differ noticeably between the two groups, we 
cannot declare the differences to be significant. However, more intensive sampling 
during the onset and recovery phases may greatly increase precision. It is instructive to 
compare Figures A.18 and A.11 – the latter being a panel plot of the observed core body 
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temperature profiles for stallions challenged with the KY-84 strain of EAV from Chapter 
3 – and the corresponding onset and recovery plots 4.7 and 3.7. The highly precise 
posterior credible interval for recovery in the KY-84 group in Figure 3.7 is due to the 
combination of (a) the similarity of the individual recovery trajectories in that group, and 
(b) the presence of adequate numbers of observations sampled during the recovery phase. 
 
Figure 4.7. Estimated onset and recovery times, with posterior 95% credible intervals, 
for wild lean ducks challenged with AIV 
4.5.  DISCUSSION 
For several reasons the normal-errors NLHM from Chapters 2 and 3 is not 
appropriate for modeling viral load in EI studies. Viral load does not vary in uninfected 
individuals prior to challenge nor after clearance, so that the constant variance 
assumption is clearly violated. Furthermore, viral load must be positive, so it makes no 
sense to model a subject’s viral load at each time point as a normal random variable. 
Finally, during infection it may happen the variability in viral load increases as the mean 
viral load increases. We have proposed a NLHM which better reflects viral load 
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dynamics in EI studies. Although we modeled the individual responses as Poisson 
random variables, there are other distributions that we might have chosen to address these 
shortcomings of the normal-errors NLHM. 
Our model is not mechanistic, in the sense that the choice of response function is 
not informed by biological knowledge of viral kinetics. There are at least two other 
domains in which researchers have developed both mechanistic and empirical NLHM’s 
for studying the time course of viral load dynamics. A discussion of those cases will 
provide a helpful context within which to interpret our findings. 
In AIDS research, early efforts to model HIV dynamics in vivo date to the mid-
1990’s. It was known that infected individuals treated with reverse transcriptase or 
protease inhibitors experienced an exponential decline of virus in plasma and a 
simultaneous increase in CD4 cell counts (Herz et al 1996).  Compartmental models, 
very much like the susceptible-infected-recovered (SIR) models used in the study of 
infectious disease transmission in epidemics, were developed to model the observed viral 
dynamics (Perelson et al 1996, Ho et al 1995, Wei et al 1995). These models were based 
on differential equations that describe the interactions among cells susceptible to 
infection, infected cells and free virus (Huang et al. 2006). They have been instrumental 
in understanding HIV pathogenesis and developing treatment strategies. 
Wu et al (1998) extended the work of Perelson et al. by placing it in the 
framework of the normal-errors NLHM. Fitgerald et al. (2002) proposed a normal-errors 
NLHM of the HIV “rebound effect,” an increase in viral load which occurs in some 
patients following the initial decrease caused by initiation of antiretroviral therapy. Both 
of these were implemented in the nonlinear mixed model (NLMM) framework. Several 
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authors have reported on the application of Bayesian methods to the modeling of HIV 
dynamics including Frost et al. (2001), Han et al. (2002), Wolf et al. (2002), Wu (2005), 
Huang et al. (2006). A recent paper by Huang (2013) describes a model more similar to 
our own, namely, a piecewise Bayesian NLHM of viral load changes for HIV. The model 
includes parameters that identify transition points in the HIV trajectory, such as the 
previously mentioned rebound effect. Unlike the other HIV models we have described, it 
is empirical rather than mechanistic. Its purpose (like that of our infection response 
models) is to describe and estimate macro-level features of the response trajectories. 
Efforts have also been made to apply NLHM to hepatitis viral kinetics. Neumann 
et al. (1998) proposed a mechanistic model of hepatitis C virus (HCV) dynamics in 
response to interferon-𝛼 therapy.  O’Sullivan et al. (2008) developed a normal-errors 
NLHM based on a logistic response function to empirically quantify long-term within- 
and between-subjects HCV variation untreated, chronically infected individuals. Snoeck 
et al. (2010) introduced a mechanistic, normal-errors NLHM capable of flexibly 
modeling a range of HCV responses to treatment with peginterferon 𝛼-2a±ribivarin.  
4.5.1. Illustrative examples 
In both the HIV and the hepatitis C models discuss above, the focus is on the 
effect of therapeutic interventions on viral load in chronically infected individuals. The 
normal-errors assumption is reasonable in those cases because subjects have established a 
nonzero baseline level around which viral load fluctuates over time. In EI studies, the 
interest centers on the response to acute infection in individuals not infected at the 
beginning of the experiment. Thus normal-error models are not appropriate.  
 
93 
 
In both of the illustrative examples we noted a lack of convergence in the MCMC 
chains for certain of the onset and recovery parameters – both the population effects and 
their variance components. In particular, this was observed for the recovery parameters 
for the wild lean group in the influenza example, and the onset parameters in both the 
COPD and control groups in the RV-16 example. This problem was not encountered in 
the lymphocyte and febrile response examples in Chapter 3. These difficulties are 
symptomatic of two fundamental issues that can be addressed through improved study 
design. First, the response variable may have been sampled with insufficient intensity 
during the onset and recovery phases. Second, the individual responses within a particular 
group may be too dissimilar to permit them to be summarized by a single population 
response curve. The lesson is that, in addition to the number of individuals per group, the 
investigator should give careful thought to the sampling schedule and to the degree of 
heterogeneity permitted among the individuals in each group. For example, if there are 
significant differences in the way that male and females, or younger and older 
individuals, respond to a particular infection, then consideration should be given to 
restricting the samples accordingly, in order to reduce noise and increase power.  
Wu et al (1998), Wu and Ding (2000) and Wu (2005) address the critical 
importance of the sampling schedule in viral load studies. Although their focus is studies 
of HIV dynamics, their comments are equally relevant to EI studies. For example Wu 
(1998) suggests “sampling as frequently as possible during the first 8 hours until one 
captures the drug effect time (the time that viral load starts to drop).” Obviously in EI 
studies viral load will increase following inoculation rather than dropping following 
treatment (as in HIV studies), but the message is the same: frequent sampling during the 
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incubation period is important for modeling the true onset trajectory accurately. 
Typically, however, in EI studies viral load is sampled at most daily during the first few 
days, and less frequently thereafter. A study by Harris and McGwaltney (1996) clearly 
demonstrates the rapid onset of rhinovirus infection. In eleven volunteers challenged with 
rhinovirus type 39, mean time of symptom onset occurred was less than 2 hours and the 
mean time to first detectable viral shedding was 11.3 hours. In this particular scenario it 
would seem advisable to sample viral load at least every three or four hours over the first 
day post-inoculation. Wu and colleagues suggest the use of Monte Carlo simulation as an 
aid to determining an adequate sampling schedule. 
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CHAPTER FIVE 
Summary and future directions 
5.1. Nonlinear hierarchical models for longitudinal EI studies 
Longitudinal infection response data arise in many experimental infection studies 
including those designed to demonstrate vaccine efficacy, explore disease etiology, 
pathogenesis and transmission, or understand the host immune response to infection. 
Very often such data are analyzed with inefficient and arguably inappropriate statistical 
methods, frequently RM-ANOVA. This is not unique to EI studies; it has been noted by 
researchers in many fields (Jang 2013, Matthews 1990). Major advances in methods for 
analyzing longitudinal data that have occurred over the past fifty years, but investigators 
in some disciplines – including those that utilize EI studies – continue to rely almost 
exclusively on familiar, classical approaches. In some cases, such as EI where infection 
responses are inherently nonlinear, newer methods may offer substantial gains in 
accuracy and precision of parameter estimation and power. Our aim was to propose an 
alternative approach to the analysis of longitudinal data from EI studies that incorporates 
recent developments in the areas of nonlinear hierarchical models and Bayesian statistics.  
 In Chapter 2 we introduced a basic, single-peaked model for a symmetric 
infection response which was based on the normal-errors NLHM with a Gaussian mean 
response function. The parameters of that model correspond directly to biologically 
meaningful properties of the infection response, including baseline, peak intensity, time 
to peak and spread. In Monte Carlo simulation studies the NLHM outperformed RM-
ANOVA across a broad range of scenarios, and under certain conditions the 
improvement was substantial. Estimation in the NLHM was more precise than RM-
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ANOVA for all model parameters, and less biased for peak intensity and duration 
parameters. We demonstrated the effects of the sampling schedule, interindividual 
response variability and misspecification of the mean response function on estimation 
and inference. Finally we illustrated the application of the symmetric NLHM to real data 
as a frequentist nonlinear mixed model.  
 In Chapter 3 we extended the basic, symmetric response model from Chapter 1 by 
incorporating a piecewise, half-Gaussian response function. Piecewise longitudinal 
response models have been applied successfully in several fields including ecology 
(Huisman et al 1993), cancer research (Müller and Rosner 1997), HIV/AIDS research 
(Huang 2012) and functional magnetic resonance imaging (Gössl et al 2001). We chose 
to implement the model as a Bayesian hierarchical nonlinear model to overcome 
convergence problems and avoid reliance on asymptotic results associated with the 
frequentist framework. The latter concern is relevant given the generally small-to-
moderate sample sizes associated with EI studies. Through illustrative examples we 
demonstrated the application to the description of lymphocyte decline following 
experimental challenge with EAV and the comparison of febrile responses to challenge 
with different strains of EAV. Finally we proposed a method for estimating infection 
response onset and recovery times from the fitted model. 
 In Chapter 4 we considered modeling of viral load in EI studies. Mechanistic viral 
load models have been developed for individuals chronically infected with HIV and 
hepatitis, and in these cases a normal-errors model is appropriate. In EI studies, however, 
it is not because viral load does not vary prior to challenge and during the incubation 
period, nor after elimination of the infection. We therefore proposed a NHLM with the 
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individual responses at each time point modeled as a Poisson random variable with the 
means across time points related through a Tricube mean response function. We 
demonstrated application of the model to compare the viral load trajectories in COPD 
patients and controls challenged with human rhinovirus, and the time course of influenza 
A virus shedding in birds with different, experimentally controlled body conditions. We 
discussed estimation of onset and recovery times within the viral load model. 
5.2. Limitations and open questions 
As we conjectured, the NLHM clearly offer potential gains in estimation and 
precision of parameter estimation and power over RM-ANOVA. The extent to which 
these gains will be realized in any particular example depends on a number of factors. 
Among them are the true effect size, the numbers of subjects per group, the number and 
configuration of measurement occasions for each individual, and the amount of 
interindividual response variability. Consultation with a biostatistician from the early 
stages of study design is highly advisable. 
Numerous avenues exist for future work in this area. The asymmetric model 
accommodates many more response shapes than the symmetric model, but it is still 
limited to single-peaked responses. Some response variables may follow other 
trajectories. For example, a proportion of stallions infected with EAV will develop 
persistent infections. The viral load in such horses will rise strongly following challenge 
and decline after peaking, but will not return to the original zero baseline. Instead it will 
stabilize at a new, nonzero baseline level. Antibody responses will exhibit a similar 
pattern. In other cases there may be more than one peak, particularly in experiments 
involving more than one challenge point. These types of response variables and 
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experiments will require different forms for the mean response function. As the response 
function increases in complexity, issues of sample size and data collection schedules 
become increasingly critical due to the need to estimate a larger number of parameters.  
The NLHM is a rich, highly flexible modeling framework with capabilities we 
have not explored in this dissertation. For example the effect of covariates such as subject 
age, gender and smoking history on the characteristics of the infection response can be 
modeled, and the response correlation structure can be explicitly modeled. Successful use 
of these features of the NLMH may require larger sample sizes and/or more intensive 
observations on individual subjects. Monte Carlo simulation studies can be utilized to 
explore feasibility and sample size requirements in the experimental design phase.  
Another area we have not explored in great depth is model building and selection.  
The NLHM presents an impressive array of modeling options available to the data 
analyst. With this flexibility comes the need for tools to compare candidate models. 
Systematic and objective methods are needed to decide, for example, whether an 
assumption of equal variance across treatment groups is justified. Such questions were 
not a primary focus of this work.  
5.3. Broader applicability 
Peaked data arise in many contexts in which there is interest in experimentally 
studying an acute response to an external stimulus.  Researchers in a number of fields 
have adopted the NLHM approach pioneered in pharmacokinetics and 
pharmacodynamics for analyzing this time of nonlinear, longitudinal data. Jang et al 
(2013) applied piecewise NLHM’s to the analysis of cardiac function (heart rate, 
coronary flow, and left ventricle developed pressure) in experiments on myocardial 
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ischemia/reperfusion injury (I/R). The goal of such models is to assess the effect of 
treatments designed to protect against I/R injury.  G ö ssl et al (2001) developed a 
piecewise Bayesian NLHM of the hemodynamic response function (HRF) which arises in 
functional magnetic resonance imaging. The HRF reflects acute changes in blood flow 
and oxygenation levels in response to neuronal stimulation in the brain.  Insulin and 
blood glucose levels follow an acute, single-peaked response pattern following food 
consumption, and insulin and blood glucose response curves are commonly used in 
nutrition and diabetes research (Fernandez-Raudales 2012). Salivary cortisol is a 
commonly used as a biomarker for stress, and salivary cortisol profiles are used to 
characterize the response to acute stressors (Sanchez 2012). Numerous other examples 
can be cited. There remain disciplines within which classical methods such as RM-
ANOVA for modeling longitudinal data are still predominant. The models and 
approaches introduced in this dissertation may have applications in a number of domains 
outside of EI studies. 
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APPENDIX A. 
Supplemental material for illustrative applications 
  
 
101 
 
§ 2.4.  Febrile response to EAV in horses (symmetric model) 
 
Figure A.1. Observed subject-specific core body temperature profiles for eight mares 
experimentally challenged with the Bucyrus strain of EAV 
 
Figure A.2. Observed subject-specific core body temperature profiles for eight stallions 
experimentally challenged with the KY-84 strain of EAV 
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Figure A.3. Estimated subject-specific febrile response functions 
 
 
Figure A.4. Composite residual plot  
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§ 3.4.1.  Lymphocyte response to EAV infection in horses 
  myModel <- function() { 
     
    for (i in 1:n) { 
      Response[i] ~ dnorm(f[i], pow(s.e,-2)) 
      f[i] <- step(p[Subject[i]]-DPI[i])*(B[Subject[i]]+I[Subject[i]]*exp(-
pow(DPI[i]-p[Subject[i]],2)/(2*pow(l[Subject[i]],2)))) +  
               step(DPI[i]-p[Subject[i]])*(B[Subject[i]]+I[Subject[i]]*exp(-
pow(DPI[i]-p[Subject[i]],2)/(2*pow(r[Subject[i]],2))))  
      res[i] <- Response[i] - f[i] 
    } 
     
    # Hyperparameters for mean, standard deviation, baseline and intensity 
      for (j in 1:8) { 
        B[j] ~ dnorm(m.B,pow(s.B,-2)) 
        I[j] ~ dnorm(m.I,pow(s.I,-2)) 
        p[j] ~ dnorm(m.p,pow(s.p,-2)) 
        l[j] ~ dlnorm(m.log_l,pow(s.log_l,-2)) 
        r[j] ~ dlnorm(m.log_r,pow(s.log_r,-2)) 
      } 
     
    # Hyperpriors 
      m.B ~ dunif(0,5) 
      m.I ~ dunif(-10,0) 
      m.p ~ dunif(0,42)        
      m.log_l ~ dunif(0,5) 
      m.log_r ~ dunif(0,5) 
             
      s.e ~ dunif(0,100) 
      s.B ~ dunif(0,6) 
      s.I ~ dunif(0,6) 
      s.p ~ dunif(0,22) 
      s.log_l ~ dunif(0,2) 
      s.log_r ~ dunif(0,2) 
     
    # FWHM 
      HWHM.o <- 2.355*0.5*exp(m.log_l) 
      HWHM.r <- 2.355*0.5*exp(m.log_r) 
      FWHM <- HWHM.l + HWHM.r  
  } 
Figure A.5. JAGS model for lymphocyte example 
  
 
104 
 
Table A.1. Posterior summary for lymphocyte example 
3 chains, each with 1e+05 iterations (first 25000 discarded) 
 n.sims = 225000 iterations saved 
          mu.vect sd.vect     2.5%      25%      50%      75%    97.5%  Rhat  n.eff 
FWHM        5.462   0.627    4.382    5.054    5.414    5.816    6.814 1.001  17000 
HWHM.o      4.051   0.528    3.064    3.711    4.036    4.374    5.116 1.001  26000 
HWHM.r      1.412   0.307    1.182    1.233    1.315    1.471    2.233 1.001   9100 
m.B         1.523   0.083    1.358    1.475    1.523    1.572    1.688 1.001  93000 
m.I        -0.834   0.096   -1.027   -0.890   -0.834   -0.778   -0.644 1.001  39000 
m.log_l     1.227   0.132    0.956    1.148    1.232    1.312    1.469 1.002  18000 
m.log_r     0.164   0.172    0.004    0.046    0.110    0.222    0.640 1.001  27000 
m.p         8.265   0.365    7.640    8.004    8.231    8.499    9.046 1.001 220000 
s.B         0.215   0.081    0.115    0.162    0.198    0.249    0.417 1.001  44000 
s.I         0.210   0.106    0.052    0.142    0.193    0.259    0.466 1.001 220000 
s.e         0.141   0.011    0.122    0.133    0.140    0.148    0.164 1.001  87000 
s.log_l     0.167   0.139    0.008    0.071    0.139    0.227    0.502 1.001   5300 
s.log_r     0.923   0.548    0.089    0.453    0.849    1.377    1.935 1.001  29000 
s.p         0.316   0.266    0.010    0.124    0.259    0.439    0.961 1.001  70000 
deviance -131.779   9.666 -148.543 -138.648 -132.513 -125.708 -110.832 1.001  64000 
 
Figure A.6. Observed subject-specific lymphocyte profiles 
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Figure A.7. Estimated subject-specific lymphocyte response functions 
 
Figure A.8. Composite residual plot 
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§ 3.4.2.  Febrile response to EAV infection in horses (asymmetric model) 
myModel <- function() { 
     
    for (i in 1:n_A) { 
      y_A[i] ~ dnorm(f_A[i], pow(s.e,-2)) 
      f_A[i] <- ifelse(p_A[Subject_A[i]]>=DPI_A[i],  
                       B_A[Subject_A[i]]+I_A[Subject_A[i]]*exp(-pow(DPI_A[i]-
p_A[Subject_A[i]],2)/(2*pow(l_A[Subject_A[i]],2))), 
                       B_A[Subject_A[i]]+I_A[Subject_A[i]]*exp(-pow(p_A[Subject_A[i]]-
DPI_A[i],2)/(2*pow(r_A[Subject_A[i]],2)))) 
      res_A[i] <- y_A[i] - f_A[i] 
    } 
     
    for (i in 1:n_B) { 
      y_B[i] ~ dnorm(f_B[i], pow(s.e,-2)) 
      f_B[i] <- ifelse(p_B[Subject_B[i]]>=DPI_B[i],  
                       B_B[Subject_B[i]]+I_B[Subject_B[i]]*exp(-pow(DPI_B[i]-
p_B[Subject_B[i]],2)/(2*pow(l_B[Subject_B[i]],2))), 
                       B_B[Subject_B[i]]+I_B[Subject_B[i]]*exp(-pow(p_B[Subject_B[i]]-
DPI_B[i],2)/(2*pow(r_B[Subject_B[i]],2)))) 
      res_B[i] <- y_B[i] - f_B[i] 
    } 
     
    # Hyperparameters for mean, standard deviation, baseline and intensity 
      for (j in 1:8) { 
       B_A[j] ~ dnorm(m.B_A, pow(s.B_A,-2)) 
        I_A[j] ~ dnorm(m.I_A, pow(s.I_A,-2)) 
        p_A[j] ~ dnorm(m.p_A, pow(s.p_A,-2)) 
        logl_A[j] ~ dnorm(m.logl_A,pow(s.logl_A,-2))   
        logr_A[j] ~ dnorm(m.logr_A,pow(s.logr_A,-2))  
        l_A[j] <- exp(logl_A[j]) 
        r_A[j] <- exp(logr_A[j]) 
      } 
      for (j in 1:8) { 
       B_B[j] ~ dnorm(m.B_B, pow(s.B_B,-2)) 
        I_B[j] ~ dnorm(m.I_B, pow(s.I_B,-2)) 
        p_B[j] ~ dnorm(m.p_B, pow(s.p_B,-2)) 
        logl_B[j] ~ dnorm(m.logl_B,pow(s.logl_B,-2))   
        logr_B[j] ~ dnorm(m.logr_B,pow(s.logr_B,-2))   
        l_B[j] <- exp(logl_B[j]) 
        r_B[j] <- exp(logr_B[j]) 
      } 
     
    # Hyperpriors 
      m.B_A ~ dunif(90,110); m.B_B ~ dunif(90,110) 
      m.I_A ~ dunif(0,20); m.I_B ~ dunif(0,20) 
      m.p_A ~ dunif(0,42); m.p_B ~ dunif(0,42)      
      m.logl_A ~ dunif(0,5); m.logl_B ~ dunif(0,5)  
      m.logr_A ~ dunif(0,5); m.logr_B ~ dunif(0,5) 
     
      s.e ~ dunif(0,100) 
      s.B_A ~ dunif(0,10); s.B_B ~ dunif(0,10) 
      s.I_A ~ dunif(0,6); s.I_B ~ dunif(0,6) 
      s.p_A ~ dunif(0,12); s.p_B ~ dunif(0,12) 
      s.logl_A ~ dunif(0,4); s.logl_B ~ dunif(0,4) 
      s.logr_A ~ dunif(0,4); s.logr_B ~ dunif(0,4) 
     
    # Differences 
      m.B_diff <- m.B_B - m.B_A 
      m.I_diff <- m.I_B - m.I_A 
      m.p_diff <- m.p_B - m.p_A 
      HWHM.l_A <- 0.5*2.355*exp(m.logl_A); HWHM.l_B <- 0.5*2.355*exp(m.logl_B) 
      HWHM.r_A <- 0.5*2.355*exp(m.logr_A); HWHM.r_B <- 0.5*2.355*exp(m.logr_B) 
      FWHM_A <- HWHM.l_A + HWHM.r_A; FWHM_B <- HWHM.l_B + HWHM.r_B 
      FWHM_diff <- FWHM_B - FWHM_A 
      m.logl_diff <- m.logl_B - m.logl_A 
      m.logr_diff <- m.logr_B - m.logr_A 
  }  
Figure A.9. JAGS model for febrile response example   
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Table A.2. Posterior summary for febrile response example 
 
3 chains, each with 1e+05 iterations (first 25000 discarded) 
 n.sims = 225000 iterations saved 
            mu.vect sd.vect    2.5%     25%     50%     75%   97.5%  Rhat  n.eff 
FWHM_A        5.693   0.694   4.813   5.322   5.611   5.941   7.026 1.003   1000 
FWHM_B        5.590   0.419   4.812   5.324   5.574   5.836   6.459 1.001  16000 
FWHM_diff    -0.103   0.807  -1.620  -0.474  -0.048   0.353   1.155 1.004   2200 
HWHM.l_A      4.260   0.400   3.510   3.993   4.248   4.508   5.075 1.003   1100 
HWHM.l_B      4.260   0.415   3.473   3.998   4.250   4.507   5.105 1.001  11000 
HWHM.r_A      1.433   0.540   1.182   1.231   1.309   1.458   2.433 1.002   4000 
HWHM.r_B      1.330   0.139   1.182   1.229   1.294   1.392   1.672 1.001  33000 
m.B_A        99.372   0.202  98.967  99.254  99.374  99.492  99.769 1.001  19000 
m.B_B        99.261   0.191  98.878  99.147  99.261  99.375  99.643 1.001 160000 
m.B_diff     -0.112   0.277  -0.659  -0.285  -0.113   0.061   0.441 1.001  80000 
m.I_A         3.463   0.388   2.687   3.232   3.463   3.694   4.241 1.001  27000 
m.I_B         4.669   0.281   4.107   4.504   4.669   4.834   5.223 1.001 110000 
m.I_diff      1.206   0.479   0.253   0.908   1.205   1.504   2.157 1.001 110000 
m.logl_A      1.281   0.094   1.092   1.221   1.283   1.343   1.461 1.003   1100 
m.logl_B      1.281   0.097   1.082   1.222   1.284   1.342   1.467 1.001  11000 
m.logl_diff   0.000   0.135  -0.268  -0.087   0.000   0.087   0.265 1.002   3800 
m.logr_A      0.168   0.205   0.004   0.044   0.106   0.214   0.726 1.001   5600 
m.logr_B      0.117   0.096   0.004   0.043   0.095   0.167   0.351 1.001  13000 
m.logr_diff  -0.051   0.227  -0.626  -0.121  -0.013   0.070   0.269 1.002   3700 
m.p_A         7.776   0.260   7.307   7.599   7.758   7.942   8.323 1.004    720 
m.p_B         7.067   0.207   6.640   6.941   7.075   7.200   7.461 1.001  60000 
m.p_diff     -0.709   0.328  -1.389  -0.919  -0.697  -0.486  -0.092 1.003   1200 
s.B_A         0.455   0.209   0.172   0.317   0.415   0.546   0.968 1.001  26000 
s.B_B         0.435   0.197   0.152   0.304   0.401   0.527   0.915 1.001  38000 
s.I_A         0.905   0.404   0.349   0.637   0.830   1.084   1.909 1.001  16000 
s.I_B         0.551   0.334   0.053   0.328   0.505   0.713   1.337 1.006   1600 
s.e           0.679   0.032   0.619   0.657   0.678   0.701   0.747 1.001  50000 
s.logl_A      0.095   0.090   0.003   0.034   0.073   0.129   0.315 1.001   6100 
s.logl_B      0.182   0.100   0.026   0.117   0.168   0.230   0.422 1.002   6400 
s.logr_A      0.781   0.711   0.035   0.298   0.571   1.014   2.897 1.003   1200 
s.logr_B      0.235   0.186   0.011   0.108   0.198   0.312   0.699 1.002   3000 
s.p_A         0.228   0.199   0.010   0.087   0.180   0.312   0.735 1.002   5100 
s.p_B         0.271   0.193   0.015   0.130   0.241   0.369   0.739 1.003   1700 
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Figure A.10. Observed subject-specific core body temperature profiles for eight mares 
experimentally challenged with the Bucyrus strain of EAV 
 
 
Figure A.11. Observed subject-specific core body temperature profiles for eight stallions 
experimentally challenged with the KY-84 strain of EAV 
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Figure A.12. Estimated subject-specific febrile response functions for eight mares 
experimentally challenged with the Bucyrus strain of EAV 
 
Figure A.13. Estimated subject-specific febrile response functions for eight stallions 
experimentally challenged with the KY-84 strain of EAV 
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Figure A.14.  Composite residual plot for eight mares experimentally challenged with the 
Bucyrus strain of EAV 
Figure A.15.  Composite residual plot for eight stallions experimentally challenged with 
the KY-84 strain of EAV 
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§ 4.3.1. Effect of body condition on viral shedding in migratory waterfowl 
myModel <- function() { 
     
    for (i in 1:n_A) { 
      y_A[i] ~ dnorm(f_A[i], pow(s.e,-2)) 
      u_A[i] <- ifelse(DPI_A[i] > p_A[Subject_A[i]], (DPI_A[i] - 
p_A[Subject_A[i]])/r_A[Subject_A[i]], (DPI_A[i] - p_A[Subject_A[i]])/l_A[Subject_A[i]]) 
      Infected_A[i] <- (u_A[i] > -1) * (u_A[i] < 1) 
      f_A[i] <- Infected_A[i] * I_A[Subject_A[i]] * (1-abs(u_A[i])^3)^3 
      res_A[i] <- y_A[i] - f_A[i] 
    } 
     
    for (i in 1:n_B) { 
      y_B[i] ~ dnorm(f_B[i], pow(s.e,-2)) 
      u_B[i] <- ifelse(DPI_B[i] > p_B[Subject_B[i]], (DPI_B[i] - 
p_B[Subject_B[i]])/r_B[Subject_B[i]], (DPI_B[i] - p_B[Subject_B[i]])/l_B[Subject_B[i]]) 
      Infected_B[i] <- (u_B[i] > -1) * (u_B[i] < 1) 
      f_B[i] <- Infected_B[i] * I_B[Subject_B[i]] * (1-abs(u_B[i])^3)^3 
      res_B[i] <- y_B[i] - f_B[i] 
    } 
     
    # Hyperparameters for mean, standard deviation, baseline and intensity 
      for (j in 1:10) { 
        I_A[j] ~ dnorm(m.I_A, pow(s.I_A,-2)) 
        p_A[j] ~ dnorm(m.p_A, pow(s.p_A,-2)) 
        l_A[j] ~ dnorm(m.l_A,pow(s.l_A,-2))   
        r_A[j] ~ dnorm(m.r_A,pow(s.r_A,-2))  
      } 
      for (j in 1:9) { 
        I_B[j] ~ dnorm(m.I_B, pow(s.I_B,-2)) 
        p_B[j] ~ dnorm(m.p_B, pow(s.p_B,-2)) 
        l_B[j] ~ dnorm(m.l_B,pow(s.l_B,-2))   
        r_B[j] ~ dnorm(m.r_B,pow(s.r_B,-2))   
      } 
     
    # Hyperpriors 
      m.I_A ~ dunif(0,1000); m.I_B ~ dunif(0,1000) 
      m.p_A ~ dunif(0,10); m.p_B ~ dunif(0,10)      
      m.l_A ~ dunif(0,m.l_A); m.l_B ~ dunif(0,m.l_B)  
      m.r_A ~ dunif(0,5); m.r_B ~ dunif(0,5) 
     
      s.I_A ~ dunif(0,500); s.I_B ~ dunif(0,500) 
      s.p_A ~ dunif(0,5); s.p_B ~ dunif(0,5) 
      s.l_A ~ dunif(0,2); s.l_B ~ dunif(0,5) 
      s.r_A ~ dunif(0,2); s.r_B ~ dunif(0,5) 
 
    # Onset and recovery 
      onset_A <- m.p_A - m.l_A; onset_B <- m.p_B - m.l_B 
      recov_A <- m.p_A + m.r_A; recov_B <- m.p_B + m.r_B 
      dur_A <- recov_A - onset_A; dur_B <- recov_B - onset_B 
     
    # Differences 
       m.I_diff <- m.I_B - m.I_A 
       m.p_diff <- m.p_B - m.p_A 
       onset_diff <- onset_B - onset_A  
       recov_diff <- recov_B - recov_A 
       dur_diff <- dur_B - dur_A 
  } 
 
Figure A.16. JAGS model for influenza A viral shedding example   
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Table A.3. Posterior summary for influenza A viral shedding example 
 
3 chains, each with 2e+05 iterations (first 50000 discarded) 
 n.sims = 450000 iterations saved 
            mu.vect sd.vect     2.5%      25%      50%      75%    97.5%  Rhat  n.eff 
dur_A         5.679   0.580    4.422    5.307    5.730    6.100    6.664 1.003    890 
dur_B         4.900   1.138    2.472    4.170    4.972    5.710    6.911 1.043     74 
dur_diff     -0.779   1.282   -3.432   -1.615   -0.733    0.109    1.603 1.031     75 
m.I_A       470.195  57.382  354.831  434.943  470.609  505.799  583.711 1.001 110000 
m.I_B       330.751  67.364  196.823  289.538  330.115  371.374  467.642 1.001  11000 
m.I_diff   -139.445  88.478 -313.574 -196.341 -139.857  -83.562   38.085 1.001  11000 
m.l_A         1.290   0.405    0.383    1.038    1.331    1.579    1.978 1.009    420 
m.l_B         1.514   0.659    0.214    1.054    1.537    1.977    2.757 1.001  15000 
m.p_A         1.877   0.293    1.310    1.690    1.871    2.056    2.479 1.002   3400 
m.p_B         2.476   0.582    1.357    2.104    2.459    2.828    3.687 1.001   8700 
m.p_diff      0.599   0.651   -0.663    0.176    0.588    1.008    1.927 1.001 170000 
m.r_A         4.389   0.425    3.409    4.126    4.460    4.729    4.971 1.001  34000 
m.r_B         3.387   0.934    1.273    2.804    3.487    4.090    4.858 1.078     52 
onset_A       0.587   0.414    0.029    0.260    0.513    0.835    1.561 1.003    950 
onset_B       0.962   0.686    0.042    0.412    0.842    1.388    2.535 1.001 250000 
onset_diff    0.375   0.801   -1.048   -0.174    0.299    0.879    2.097 1.002   2600 
recov_A       6.266   0.509    5.164    5.946    6.311    6.626    7.148 1.001  30000 
recov_B       5.862   1.091    3.520    5.168    5.934    6.632    7.795 1.044     66 
recov_diff   -0.404   1.205   -2.912   -1.182   -0.353    0.425    1.824 1.029     82 
s.I_A       165.771  49.995   97.653  131.017  156.162  189.447  291.298 1.001  51000 
s.I_B       188.991  58.930  109.989  147.662  176.860  216.648  340.856 1.001 450000 
s.l_A         1.344   0.320    0.771    1.099    1.332    1.587    1.941 1.007    310 
s.l_B         2.735   0.731    1.609    2.193    2.622    3.170    4.465 1.001  22000 
s.p_A         0.928   0.275    0.553    0.738    0.876    1.057    1.607 1.001   7400 
s.p_B         1.797   0.562    1.036    1.402    1.685    2.064    3.232 1.001  97000 
s.r_A         1.899   0.088    1.673    1.854    1.923    1.967    1.997 1.001 320000 
s.r_B         3.134   0.773    1.847    2.543    3.053    3.667    4.752 1.108     23 
 
  
 
113 
 
 
Figure A.17. Observed subject-specific viral shedding profiles for ten wild-caught, 
normal treatment mallards experimentally challenged with influenza A 
 
Figure A.18. Observed subject-specific viral shedding profiles for nine wild-caught, lean 
treatment mallards experimentally challenged with influenza A 
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Figure A.19. Estimated subject-specific viral shedding responses for nine captive-bred, 
normal treatment mallards experimentally challenged with influenza A 
 
 
Figure A.20. Estimated subject-specific viral shedding responses for nine wild-caught, 
lean treatment mallards experimentally challenged with influenza A 
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Figure A.21.  Composite residual plot for nine captive-bred, normal treatment mallards 
experimentally challenged with influenza A (jittered to show overlapping values more 
clearly)  
 
Figure A.22.  Composite residual plot for nine wild-caught, lean treatment mallards 
experimentally challenged with influenza A (jittered to show overlapping values more 
clearly) 
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§ 4.3.2.  Effects of rhinovirus infection in chronic obstructive pulmonary disease 
 
  myModel <- function() { 
     
    for (i in 1:n_A) { 
      y_A[i] ~ dpois(f_A[i]) 
      u_A[i] <- ifelse(DPI_A[i] > p_A[Subject_A[i]], (DPI_A[i] - 
p_A[Subject_A[i]])/r_A[Subject_A[i]], (DPI_A[i] - p_A[Subject_A[i]])/l_A[Subject_A[i]]) 
      Infected_A[i] <- (u_A[i] > -1) * (u_A[i] < 1) 
      f_A[i] <- Infected_A[i] * I_A[Subject_A[i]] * (1-abs(u_A[i])^3)^3 
      res_A[i] <- y_A[i] - f_A[i] 
     }    
    for (i in 1:n_B) { 
      y_B[i] ~ dpois(f_B[i]) 
      u_B[i] <- ifelse(DPI_B[i] > p_B[Subject_B[i]], (DPI_B[i] - 
p_B[Subject_B[i]])/r_B[Subject_B[i]], (DPI_B[i] - p_B[Subject_B[i]])/l_B[Subject_B[i]]) 
      Infected_B[i] <- (u_B[i] > -1) * (u_B[i] < 1) 
      f_B[i] <- Infected_B[i] * I_B[Subject_B[i]] * (1-abs(u_B[i])^3)^3 
      res_B[i] <- y_B[i] - f_B[i] 
     } 
     
    # Hyperparameters for mean, standard deviation, baseline and intensity 
      for (j in 1:12) { 
        I_A[j] ~ dnorm(m.I_A, s.I_A^(-2)) 
        p_A[j] ~ dnorm(m.p_A, s.p_A^(-2)) 
        l_A[j] ~ dnorm(m.l_A, s.l_A^(-2)) 
        r_A[j] ~ dnorm(m.r_A, s.r_A^(-2)) 
      } 
      for (j in 1:11) { 
        I_B[j] ~ dnorm(m.I_B, s.I_B^(-2)) 
        p_B[j] ~ dnorm(m.p_B, s.p_B^(-2)) 
        l_B[j] ~ dnorm(m.l_B, s.l_B^(-2)) 
        r_B[j] ~ dnorm(m.r_B, s.r_B^(-2)) 
      } 
     
    # Hyperpriors 
      m.I_A ~ dunif(0,1500); m.I_B ~ dunif(0,1500) 
      m.p_A ~ dunif(0,42); m.p_B ~ dunif(0,42)       
      m.l_A ~ dunif(0,50); m.l_B ~ dunif(0,50) 
      m.r_A ~ dunif(0,50); m.r_B ~ dunif(0,50) 
         
      s.I_A ~ dunif(0,500); s.I_B ~ dunif(0,500) 
      s.p_A ~ dunif(0,12); s.p_B ~ dunif(0,12) 
      s.l_A ~ dunif(0,m.l_A); s.l_B ~ dunif(0,m.l_B) 
      s.r_A ~ dunif(0,5); s.r_B ~ dunif(0,5) 
     
    # Onset and recovery 
      onset_A <- m.p_A - m.l_A; onset_B <- m.p_B - m.l_B 
      recov_A <- m.p_A + m.r_A; recov_B <- m.p_B + m.r_B 
      dur_A <- recov_A - onset_A; dur_B <- recov_B - onset_B 
     
    # Differences 
      m.I_diff <- m.I_B - m.I_A 
      m.p_diff <- m.p_B - m.p_A 
      onset_diff <- onset_B - onset_A  
      recov_diff <- recov_B - recov_A 
      dur_diff <- dur_B - dur_A 
  } 
Figure A.23. JAGS model for rhinovirus-COPD example   
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Table A.4. Posterior summary rhinovirus for COPD example 
 
            mu.vect sd.vect     2.5%      25%      50%      75%    97.5%  Rhat  n.eff 
dur_A        18.132   1.489   15.209   17.127   18.133   19.134   21.059 1.019    110 
dur_B        17.079   1.636   13.902   15.972   17.069   18.179   20.308 1.001  52000 
dur_diff     -1.052   2.212   -5.369   -2.546   -1.058    0.439    3.295 1.010    220 
m.I_A       550.169  47.313  456.112  520.565  550.149  579.700  644.467 1.001 220000 
m.I_B       610.179  83.490  442.470  558.498  610.429  662.020  777.665 1.001  98000 
m.I_diff     60.010  95.932 -130.913   -1.072   60.162  121.222  251.366 1.001 110000 
m.l_A         0.748   0.408    0.059    0.425    0.735    1.054    1.527 1.280     12 
m.l_B         1.290   0.622    0.148    0.848    1.277    1.704    2.562 1.001  64000 
m.p_A         3.293   0.816    1.588    2.787    3.315    3.818    4.870 1.004   1700 
m.p_B         2.773   1.062    0.832    2.052    2.726    3.425    5.020 1.001 220000 
m.p_diff     -0.520   1.339   -3.026   -1.425   -0.564    0.331    2.243 1.001   7800 
m.r_A        17.383   1.437   14.564   16.413   17.385   18.351   20.206 1.001  35000 
m.r_B        15.789   1.527   12.808   14.758   15.784   16.817   18.797 1.001  54000 
onset_A       2.544   0.894    0.703    1.965    2.560    3.135    4.284 1.035     68 
onset_B       1.483   1.045    0.061    0.651    1.323    2.122    3.869 1.001 450000 
onset_diff   -1.062   1.374   -3.476   -2.027   -1.159   -0.192    1.872 1.021    100 
recov_A      20.676   1.647   17.425   19.574   20.679   21.783   23.900 1.001  30000 
recov_B      18.562   1.827   15.085   17.320   18.526   19.756   22.262 1.001  89000 
recov_diff   -2.114   2.459   -6.870   -3.780   -2.137   -0.472    2.767 1.001  39000 
s.I_A       148.230  40.478   91.780  119.987  140.924  167.901  247.524 1.001 200000 
s.I_B       247.802  67.127  150.960  198.981  235.444  283.787  416.018 1.001  24000 
s.l_A         1.205   0.431    0.479    0.917    1.173    1.448    2.170 1.682      6 
s.l_B         2.237   0.609    1.357    1.802    2.128    2.554    3.749 1.001  67000 
s.p_A         2.655   0.683    1.695    2.177    2.533    2.993    4.326 1.001   9600 
s.p_B         3.975   1.599    1.917    2.834    3.613    4.726    8.142 1.001   9500 
s.r_A         4.951   0.048    4.823    4.931    4.966    4.986    4.999 1.001 190000 
s.r_B         4.848   0.140    4.480    4.784    4.889    4.953    4.996 1.001 450000 
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Figure A.24. Observed nasal viral load profiles for twelve healthy controls 
experimentally challenged with RV-16 
 
Figure A.25. Observed nasal viral load profiles for eleven subjects with COPD 
experimentally challenged with RV-16 
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Figure A.26. Estimated subject-specific viral shedding responses for twelve healthy 
controls experimentally challenged with RV-16 
 
Figure A.27. Estimated subject-specific viral shedding responses for eleven subjects with 
COPD experimentally challenged with RV-16  
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Figure A.28.  Composite residual plot for twelve healthy controls experimentally 
challenged with RV-16 (jittered to show overlapping values more clearly)  
 
Figure A.29.  Composite residual plot for eleven subjects with COPD experimentally 
challenged with RV-16 (jittered to show overlapping values more clearly)   
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